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STING-dependent Type I IFN responses have taken on heightened interest with the 
realization that STING agonists could be an important adjunct therapy to the cell-cycle 
check point inhibitors being used against several cancers. Intravesical instillation of BCG 
remains at the heart of bladder cancer immunotherapy to specifically treat the non-muscle 
invasive forms of this tumor (NMIBC) that accounts for more than 75% of the cases. 
Besides being an effective immunodominant antigenic vessel, BCG combined with Type I 
IFN (IFN-αβ ) shows remarkable promise against bladder cancer, even in patients’ 
refractory to BCG-only immunotherapy. The non-canonical activator of STING, c-di-
AMP, contributes to induction of Type I IFN as well as the activation of pro-inflammatory 
cytokines from mammalian myeloid cells. Pathogenic prokaryotes have evolved well-
established mechanisms of synthesis and release of cyclic di-nucleotides including c-di-
AMP that are important for basic physiological regulation as well as in the pathogenesis of 
infection. Mycobacterium tuberculosis encodes a critical enzyme, the cyclase, disA 
(Rv3586) that plays an important role in bacterial pathogenesis.  M. tuberculosis disA is 
responsible for c-di-AMP synthesis that is a potent inducer of STING-dependent Type I 
IFN production by macrophages. We generated a recombinant BCG strain that 
overexpresses (BCG-disA OE) c-di-AMP, induces STING/TBK1/IFN- . We then tested 
these strains in rodent model of urinary bladder cancer for their immunotherapeutic 
potential. Our preliminary results show an improved treatment outcome in the in vivo 
bladder cancer model and predict STING agonist like properties of c-di-AMP 
overexpressing BCG. Further investigations are needed to identify the direct 
immunomodulatory role of BCG-disA OE at the tumor microenvironment. We do not rule 
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out the possibility of checkpoint inhibitor and STING agonist like BCG based combination 
therapy to test the immunotherapeutic potential of BCG against NMIBC in general and 
BCG-refractive cases, in particular. 
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a. Tuberculosis and BCG vaccine 
With an estimated 10.4 million incident cases and 1.7 million deaths reported in 2016, 
tuberculosis (TB) remains one of the top infectious killers of humanity. The resurgence of 
TB as a global epidemic has been triggered by the HIV/AIDS pandemic, and the emergence 
of drug-resistant strains of Mycobacterium tuberculosis (M.tb), among other factors (WHO 
global tuberculosis, 2017). 
TB is the leading cause of mortality in HIV-positive individuals [1]. For the last 90 years, 
Bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, remains 
the only available vaccine against TB, and it is widely administered to infants in areas 
endemic to TB. The vaccine has been effective in the prevention of extra-pulmonary TB in 
children, such as tuberculous meningitis and miliary TB [2], but has variable efficacy in 
adults and adolescents, ranging from 0-80% [3]. This variation has been attributed to 
human genetic variations, pre-exposure to endemic mycobacteria, and to geographical 
differences, with poor efficacy in high burden regions [3]. The insufficient protection 
conferred by BCG against pulmonary TB is believed be one of the major reasons for rapid 
spread of the disease, and therefore global efforts to improve its efficacy and to develop 
newer vaccines have intensified.  
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During initial infection, M.tb is engulfed by alveolar and interstitial lung macrophages, as 
well as lung resident dendritic cells (DCs). In these cells, M.tb is able to arrest the 
conventional phagosome maturation process, and makes the intraphagosomal compartment 
amicable for bacterial survival and their replication [4-7]. Moreover, M.tb and M.bovis are 
known to release cell wall lipids and effectors that can modulate host responses [4,8-11]. 
Host adaptive immunity is triggered by the processing of mycobacterial antigens by DCs 
that activate T lymphocytes, and is further enhanced by pro and anti-inflammatory 
cytokines released during infection, which promote myeloid and lymphocyte cell 
recruitment. Type I IFN (IFNα/ ) released during M.tb infection affect downstream 
signaling pathways and several transcription factors such as NF-κB, leading to induction 
of a large number of IFN-stimulated genes (ISGs) and production of IL-1  and other key 
pro-inflammatory mediators such as TNF, and IL-6, all of which stimulate vigorous anti-
microbial responses [12]. 
BCG is also believed to mediate immunity through the development of antigen-specific 
memory T cells [2,13], which protect against disseminated TB and TB meningitis, but the 
vaccine is inefficient against pulmonary TB in all individuals for reasons that are not well 
understood. This has led to ongoing efforts to modify and improve BCG, and a number of 
candidate vaccines are currently being evaluated in clinical trials [14]. Efforts to improve 
BCG have focused on the overexpression of immuno-dominant antigens of BCG or on the 




b. BCG as immunotherapeutic in diseases other than TB  
Ever since the introduction of BCG as a vaccine for TB, clinicians have reported the 
heterologous effects of BCG on different unrelated diseases ranging from viral infections 
to various cancers.  
In 2002, Ota et al. first highlighted that patients that received BCG priming prior to other 
neonatal vaccinations such as hepatitis B vaccine, tetanus toxoid vaccine and oral polio 
vaccine produced  a higher antibody titer as compared to the controls who did not receive 
priming with BCG [16]. Other studies corroborated the induction of superior immune 
responses to nontuberculous pathogens after BCG priming [17-20]. One conscientious 
study by Mathurin et al. in 2009 delineated the heterologous immunity conferred in an in 
vivo mouse model in the BCG immune mice to Vaccinia virus infection. This study also 
addressed that the underlying immunity conferred by BCG vaccination to the viral 
infection is due to increased induction of CD4 T cells [21]. 
Some pioneer studies indicate application of BCG as anticancer therapy and gave insights 
into usage of BCG in cancers. Holmgren, in 1936, reported application of BCG as a 
therapeutic intervention for stomach cancer in patients [61]. Subsequently, in 1959, Old et 
al., for the first time showed that intravenous injection with BCG prior to transplantable 
sarcoma tumor challenge in mice resulted in retardation of tumor growth and increased the 
survival [22]. In another study, investigators measured the immunological reaction 
induced, against different types of tumor isografts after intraperitoneal injections of BCG, 
in a mouse model and reported a superior anti-tumor immune response [23]. 
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After proving that BCG priming resulted in the retardation tumor growth and enhanced 
immune reactions, the Zbar and Tanaka group set out to study effect of vaccination for 
longer durations in a guinea pig model for with hepatocarcinoma. In addition to tumor 
regression, a notable outcome fact was that the BCG-treated guinea pigs were refractory to 
tumor development, which brought focus on the necessity of pre-existing immunity on the 
outcomes of BCG treatment [24]. In patients suffering with a wide array of gastric cancers 
(stomach, colon to pancreatic cancer), the utility and efficacy of BCG as an adjuvant to 
chemotherapy was tested for by Falk and his group. Intraperitoneally administration of 
BCG to patients followed by several cycles of oral BCG achieved prolonged survival in 
most patients [25]. Different groups suggested usage of BCG against melanoma after 
encouraging results in cancers such as adenocarcinomas and sarcoma were reported [64]. 
In a clinical study Morton et al., reported that intralesionally injected BCG in a cohort of 
36 subcutaneous melanoma patients led to complete lesion regression in 684 out of 754 
lesions [26]. In a similar clinical study, Rosenberg and Rapp reported that recurrent 
cutaneous melanoma nodules disappear 90% of the time when injected with BCG at the 
tumor site [27]. 
BCG as an immunotherapeutic was also tested in urinary cancers like prostate cancer in 
1982. In a clinical study done by Guinan et al., intratumoral injection of BCG in addition 
to conventional chemotherapy showed prolonged survival of the patients [28]. In all, BCG 
treatment as an immunotherapeutic in both in-vivo and clinical studies has been successful 
in showing tumor regression and heightened enhanced immune response.  
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c. BCG in Bladder cancer  
Bladder cancer consists of an array of diseases with wide pathologies and prognoses. 
Majority (~90%) are known to be urothelial carcinomas that primarily begin with 
transitional epithelial cells (also known as transitional cell carcinoma). The remaining 10% 
are classified as squamous cell carcinoma (which begin with flat squamous cells forming 
the bladder), small cell carcinoma (start with neuroendocrine cells of the bladder), or 
adenocarcinoma (which primarily starts with the glandular cells in the bladder) [144]. 
Approximately 75% of patients with bladder cancer present with a disease that is confined 
to the mucosa or submucosa, grouped as non-muscle invasive bladder cancer (NMIBC) 
[145]. They are moreover classified into low grade i.e. papillary (which do not invade the 
muscle layer) or they can progress to a high grade which are superficial tumors as well as 
carcinoma in situ (a flattened layer of dysplastic cells on the surface of bladder that can 
progress into muscle invasive forms of cancer) [79]. NMIBC is characterized as carcinoma 
in situ (CIS), Ta (low grade noninvasive) and T1 (muscle invasive into lamina propria) 
stages. Muscle invasive form of the disease only accounts for less than 25% of the cases 
and has a 5-year survival rate in only 50% cases. Further if the tumor metastasizes then the 
5-year survival rate is only 15% [79, 145]. 
Over the last 40 years, BCG immunotherapy remains the gold standard to treat 
NMIBC. Till date, it represents the only agent known to reduce the recurrence and the 
progression into muscle invasive bladder cancer [29]. BCG immunotherapy involves 
transurethral resection of the tumor followed by intravesical instillation of BCG. It shows 
superiority to standard transurethral resection (TUR) with any chemotherapeutic agents 
like mitomycin C. BCG as an intravesical immunotherapeutic for NMIBC was pioneered 
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by Bloomberg and group [30]. They sensitized mongrel dogs with purified protein 
derivative of tuberculin, and measured the effects intravesical instillation of BCG into the 
bladders of sensitized or unsensitized dogs. They found that BCG elicited an inflammatory 
reaction, particularly in sensitized dogs, which seemed to be temporary and well-tolerated 
by subjects [30]. This pioneering study paved to the first important approach in 1976 used 
by Morales et al. to administer intravesical instillation of BCG following transurethral 
resection in 9 patients which significantly reduced the recurrence of bladder cancer [31]. 
Given the enormous number of persons currently vaccinated with BCG worldwide (more 
than 3 billion), understanding how BCG influences the host response to these wide arrays 
of diseases from infectious diseases to cancer is an important issue for clinical research and 
practice. Also, typical complete response rates for BCG treatment are 55-65% for papillary 
tumors and 70-75% for carcinoma in situ (CIS). The burden of patients with BCG 
unresponsive and relapsing disease and of those intolerant of treatment has therefore 
prompted the need for further improving the efficacy of BCG against NMIBC. 
d. Synthetic cyclic dinucleotide (CDN) STING Agoinsts in Cancer 
Immunotherapy 
In human melanomas, Gajewski et al. in 2007, employed analysis of gene expression 
profiles to reveal that Type I Interferon (IFN) is a key marker for tumors that are highly 
infiltrated with CD8+ T cells indicating for the first time that Type I IFN might be the 
important bridge between innate and adaptive immunity [32].  
In 2011, studies in animal models further elucidated the roles that Type I IFN signaling has 
in host cells and in the augmentation of a spontaneous anti-tumor CD8+ T cells  [33-34]. It 
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is now well established that Type I IFNs, produced both by innate immune cells in tumor 
microenvironment and by the tumor cells themselves, are known to mediate anti-tumor 
effects against several malignancies [33-36]. 
It wasn’t until β014, when Woo et al. showed that tumor DNA activated cytosolic STING 
pathway by triggering the production of IFN  in dendritic cells, that the role of STING 
came into focus. Their work indicated that in STING deficient hosts, localized tumors, 
were not capable of inducing a spontaneous CD8+ T cell responses, which was not observed 
when the mice were deficient in other innate signaling pathways [35]. 
The prominence of STING as a target for development of immunotherapy further came 
into light when Juan Fu and group showed that cellular cancer vaccines formulated by CDN 
ligands demonstrated in vivo antitumor efficacy via potent induction of STING. They also 
made a remarkable observation that made was this potent induction of STING led to an 
upregulation of PD-1. When they combined CDN therapy with a PD-1 blockade therapy, 
they observed tumor regression of otherwise anti-PD-1 resistant tumors [36]. 
Many groups have tried CDNs as adjuvants for activation of STING in the tumor 
microenvironment to mediating anti-tumor immunity in acute myeloid leukemia, chronic 
lymphocytic leukemia, gliomas and head and neck squamous cell carcinoma [37-40].  
The compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a flavonoid compound 
known for vascular disruption showed anti-tumor activity in mouse models, has been used 
in 1997 by Ching et al. [41] for its promising anti-cancer properties.  However, DMXAA 
failed in a phase 3 efficacy trial in non-small cell lung cancer [42].   
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Subsequent studies showed that DMXAA only bound to murine STING and not human 
STING.  This was due to the polymorphisms in the mouse and human STING proteins. 
These findings provided a mechanistic insight into for the lack of DMXAA efficacy in 
humans, as well as the rationale for the development of new pharmacologic compounds 
that potently activate human STING sensing system [42]. 
Corrales et al. studied other synthetic STING agonists and used them for intratumoral 
injections into established tumors in melanoma, colon and breast carcinoma models and 
observed marked tumor regression and systemic T cell immunity that was tumor antigen 
specific. Further they sorted mouse bone marrow derived macrophages, DCs, lymphocytes 
and endothelial cells after ex vivo stimulation with the other synthetic CDNs. They noted 
that the highest IFN  was produced by macrophages followed by DCs, and to  lesser extent 
in lymphocytes and endothelial cells [47-48]. 
A recent study by Francica et al., using knockout chimeric mouse model was able to 
highlight the other pleiotropic effects of STING activation on induction of TNF, which is 
postulated to be necessary for CDN induced necrosis. Moreover, they also illustrated that 
in addition to myeloid cells, signaling by STING is important for the role of stromal cells 
for tumor rejection [49]. 
The cancer-specific STING agonists being developed by various groups to be used as an 






 e. Genetically modified BCG for cancer immunotherapy 
Numerous independent research groups have attempted to express mammalian cytokines 
to enhance the immunotherapeutic efficacy of BCG in bladder cancer. From early on in 
bladder cancer therapy, a higher Th1 cytokine profile characterized by IL-2, IL-12 and 
IFN  in patient samples has been shown to be favorably associated with BCG response and 
tumor regression. Many groups have hence tried to express these cytokines using BCG as 
a delivery vehicle for better immunotherapy in urothelial cancers [50-56].  
Table 1. STING Agonists under different developmental stages 
Aduro Biotech 
(Berkeley, CA) 
ADU-S100, a synthetic cyclic 
dinucleotide 
 
Phase I clinical trials in solid tumors 
and lymphomas: monotherapy or in 






Preclinical; portfolio acquired from 
IFM Therapeutics (Boston, MA) in 
August 2017 








Preclinical; partnering with Cristal 
Therapeutics (Netherlands) on 





pathway modulators; orally 
bioavailable 
Preclinical; completed a $20 million 
Series A financing in December 2017 
Merck MK-1454, a synthetic cyclic 
dinucleotide 
Phase I clinical trials in solid tumors 
and lymphomas: monotherapy or in 














SB 11285, designed for 
intravenous delivery as an 
antibody–drug conjugate 
Aims to start phase Ib/II trials in liver 
cancer in 2018 
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For example, in one of the earliest studies done in a SCID mouse model with MUC-1 
positive tumors by Chung et al., showed higher growth inhibition using rBCG expressing 
tumor antigen MUC-1 plus human IL-2 (BCG-hIL2-MUC1) [57]. 
Further details of other trials that have constructed rBCG and the type of immunity 
expressed is outlined in the Table 2. 
 
Table 2. Developed rBCG strains used against Bladder cancer 
Recombinant 
Strain 
Model System used Treatment outcomes  
rBCG-IL18 In vivo mouse model and in vitro BC 
cell line (MBT-2, PEC) 
Macrophage cytotoxicity in vitro, 
IFN-  secreting cell proliferation 
rBCG-IL2 In vitro BC cell lines (PEC and MBT-
2) 
Macrophage cytotoxicity against 
MBT-2, IFN  and IL-12 induction 
rBCG-IFN-α-β  
(Pasteur strain) 
In vitro (PBMC and BC cell lines 
(T24, J82, 5637, UMUC-3, TCCSUP)) 
PBMC cytotoxic against BC cell 
lines, significantly increased IFN , 
IP-10 and IL-2  
rBCG-IFN-α-β  
(Danish strain) 
In vitro (PBMC and BC cell lines (T24 
and T5637) 
PBMC cytotoxicity against BC cell 
lines 
rBCG-IFN  Mice and in vitro (MB49 BC cells and 
splenocytes) 
Increased MHC-I induction in vitro 
in BC cells, Recruitment of CD4+ T 
cells in vivo, Increased IL-2 in vivo, 
and Increased survival of mice 
rBCG-IL2-IL18 In vitro (PEC and MBT-2 cell line) Increased IFN , TNF-α and IL-6 
rBCG-Pertussis 
toxin (SIPT) 
In vivo Mice orthotoptic tumor model Increased TNF-α and IL-10 
induction 
rBCG-IFN- α-β  In vitro (PBMCs and BC cell lines) Cytotoxicity of PBMC against BC 
cell lines and increased 
proliferation of PBMCs 
rBCG-IFN-α In vitro  Antitumor effects and Th1 
cytokines induction, superior 
response and effect when compared 
with clinical combination therapy 
of BCG+IFN-α-β  
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 Detailed discussion of further rBCG in bladder cancer and responses elicited will be 
mentioned in the following chapters. The most potent adjunct therapy so far has been Type 
I IFN (IFN α-2b) in conjugation with BCG in preclinical and further clinical trials. Recent 
work in STING-mediated Type I IFN induction in other cancers, paves way for possible 
mechanistic modifications.  
f. BCG encoding CDNs: STING agonist like BCG   
c-di-AMP, produced primarily in gram positive bacteria plays myriad roles in bacterial 
growth, regulation of virulence and even survival during adverse stress conditions. This 
activity and level of c-di-AMP at the cellular level is primarily due to two key enzymes-c-
di-AMP synthesizing enzymes, diadenylate cyclases (DACs), and degradation enzymes, 
phosphodiesterases (PDEs) [58]. The importance of disA/dacA gene in the production of 
adenylate cyclase and subsequent circularization of ATP or ADP to form c-di-AMP has 
been well characterized in many gram-positive bacteria like in S. aureus [59], L. 
monocytogenes[60], M. tuberculosis [61] and B. subtilis [62]. Genetic manipulations of 
these genes have shown a prominent role of c-di-AMP in genotoxic stress mediated DNA 
damage, homeostasis, growth of the bacteria and virulence of microorganisms in the host 
[63]. 
Small molecules like cyclic di-nucleotides (CDNs) are a class of molecules that are known 
to activate host cytosolic surveillance pathways (CSP) in eukaryotic cells through an array 
of host proteins. CDNs are produced endogenously to response of foreign DNA or secreted 
by invading pathogens. Detection of c-di-AMP, a pathogen associated molecular pattern 
(PAMP) by the host CSP induces Type I IFNs, a family of pro inflammatory cytokines [64-
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65]. The likelihood of applicability of CDNs and structurally related compounds as danger 
signal (for adjuvant therapy) was tested when c-di-IMP (synthesized from c-di-AMP 
through adenosine deamination), induced a strong in vivo as well as in vivo immune 
responses [66-67]. Other intracellular bacteria such as M. tuberculosis [61], Group B 
Streptococcus [68] and Chlamydia trachomatis [69] were found to secrete CDNs that 
activated the mammalian cGAS/STING axis. 
Another prominent mechanism of STING activation is the detection of dsDNA released 
into the cytosol. Cytosolic double stranded DNA (dsDNA) binds to enzymatic protein 
cyclic GMP-AMP (cGAMP) synthase (cGAS), that converts ATP and GTP into cGAMP 
[70]. As a damage associated molecular pattern (DAMP) molecule, cGAMP binds to 
stimulator of interferon genes (STING/TMEM173), an endoplasmic reticulum resident 
membrane protein that, after binding of cGAMP, phosphorylates adaptor protein TANK-
binding kinase 1 (TBK1). TBK1 then phosphorylates interferon response factor 3 (IRF3), 
a transcription factor that then translocates into the nucleus and mediates the transcription 
of multiple interferon-stimulated genes (ISGs), including IFNα/  and other co-regulated 
host defense pathways [71]. Both bacterial as well viral pathogens are known to exploit 
cGAS/CDN/STING pathways, for example intracellular bacterium Listeria 
monocytogenes produces cyclic-di-adenosine monophosphate (c-di-AMP) that binds to 
STING and activates IFN  and other co-regulated genes [60]. 
Host cells recognize and respond to dsDNA viruses, such as pox viruses, adenoviruses, 
gamma herpes viruses and retroviruses, by synthesizing cGAMP, that then gets transported 
to adjacent cells via gap junctions and hence activate IFNα/  synthesis in neighboring cells 
thus preventing viral dissemination [72-76]. 
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Previous findings from the Bishai Laboratory showed that M.tb synthesizes and secretes c-
di-AMP, which activates the IRF pathway and Type I IFN responses through 
cGAS/STING. Importantly, c-di-AMP overexpressing M.tb strains show attenuation of TB 
in a mouse model [77].  
The remarkable ability of bacterial CDNs and host induced cGAMP to activate 
cGAS/STING axis in immune cells make them a new class of immune modulators, called 
the ‘STING agonists’ that specifically activate Type I IFN synthesis in TLR-independent 
fashion.  
In the thesis work presented here, we developed BCG overexpressing STING agonist c-di-
AMP to test induction of STING-dependent Type I IFN and proinflammatory cytokines in 
vivo using a rodent model of urinary bladder cancer. Evidences from our in vivo 
experiments show improved immunotherapeutic potential of BCG-disA OE (Recombinant 
BCG harboring and overexpressing disA gene) over the conventional BCG in therapy, 
against bladder cancer further complementing the new era of BCG engineering to generate 





 Materials and Methods 
 
1. Bacterial strains and culture conditions:  
In this study we have used Mycobacterium bovis (M. bovis) Bacillus Calmette-Guérin 
(BCG) Pasteur strain and Mycobacterium tuberculosis (M.tb) strain CDC1551. The BCG 
Pasteur strain was a kind gift from Frank Colins from FDA.  Bacterial strains were stored 
in frozen vials at -80°C, and revived and subsequently sub-cultured in 7H9 Middlebrook 
liquid medium (Cat. B271310, Fisher Scientific) supplemented with oleic acid-albumin-
dextrose-catalase (OADC) (Cat. B11886, Fisher Scientific), 0.5% glycerol (Cat. G5516, 
Sigma) and 0.05% Tween-80 (Cat. BP338, Fisher Scientific). For gene cloning and protein 
expression studies E. coli strains DH5a (18258012, Fischer Scientific) and BL21DE3 
(C2527I, New England Biolabs Inc) strains were routinely used. A detailed description of 
different bacterial strains, plasmids and oligos presented in Table 4. 
2. Preparation of frozen stocks and competent cell preparations:  
Fresh frozen vials for M.tb and BCG strains were prepared using 108 bacilli (OD600:1) in 
7H9 Middlebrook media in 50% sterile glycerol and immediately stored at -80°C as 
described earlier [61]. For infection and instillation purposes fresh vials were revived in 
7H9 media and were grown for 5 subculture cycles to avoid variations. For competent cell 
preparations, standard protocols were followed as described elsewhere. Briefly, log phase 
(OD600:0.6-0.8) mycobacterial cultures were pelleted and repeatedly washed using 10% 
sterile glycerol solution and were finally stored in 10% glycerol in 300 µL (approximately 
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1011 cells/mL) volumes and stored at -80°C. For electroporation 100 µL competent 
(approximately 1010 cells) cells were used per 2-4 µg of plasmid. 
3. Genomic DNA isolation from M.tb-CDC 1551:  
Genomic DNA isolation was performed using CTAB method from log phase cultures of 
M.tb-CDC 1551 as described previously. The quantity and quality of high molecular 
weight genomic DNA was determined using NanoDrop and DNA agarose gel analyses, 
respectively. 
4. Cloning M. tuberculosis disA (MT3692) into mycobacterial expression vector pSD5-
hsp60: 
 Using gene-specific primers, pSD5hsp60.MT3692 (F) and pSD5hsp60.MT3692 (R), the 
disA (MT3692) gene of M.tb, (Table 3) was PCR amplified using high molecular weight 
genomic DNA isolated from M.tb CDC-1551 as the template. PCR conditions were 95°C 
for 5 minutes followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 
56°C for 30 seconds, extension at 72°C for 1 minute and a final extension step at 72°C for 
10 minutes. Gene amplicons were cloned into mycobacterial shuttle vector pSD5-hsp60 at 
the NdeI and MluI restriction sites. The clone (pSD5-hsp60-MT3692) was confirmed by 
insert release and sequence analyses.  
5. Overexpression of disA (MT3692) in BCG Pasteur:  
The construct pSD5-hsp60-MT3692 was subsequently used to transform BCG using 
electroporation method [78]. Briefly, 2-4 µg of clone (pSD5-hsp60-MT3692) was added 
to 100 µL of electrocompetent cells and mixed gently by pipetting several times. The mix 
was transferred to pre-chilled electroporation cuvettes. Moisture was removed before 
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inserting the cuvette into the device. For electroporation, the following conditions were 
used: voltage (V) β,500, β5μF and resistance 1,000Ω as per set protocol [78]. Immediately, 
1ml of 7H9 Middlebrook media devoid of antibiotic was added to cells and bacilli were 
incubated at 37°C for next 48hours with agitation. Between 50 and 100 µL of cells were 
subsequently plated on 7H11 selection plates with kanamycin (25 µg/mL). Single colonies 
were picked and were inoculated into 7H9 Middlebrook liquid medium with kanamycin 
(25 µg/mL) for subsequent propagation. Recombinant clones were confirmed using colony 
PCR against kanamycin cassette (Table 3). MT3692 overexpression phenotype of BCG-
disA OE strain was further confirmed by mRNA expression using quantitative real time 
PCR (qPCR). 
6. Colony PCR:  
For colony PCR, bacterial colonies were picked using sterile tips and were inoculated in 
50 µL of 0.1% Triton X100 made in nuclease free water and the mixture was boiled for 5 
minutes at 100°C, followed by snap chilling. Mixture was centrifuged and supernatant was 
filtered using spin-column before performing gene-specific PCR. Small volume (10 µL) of 
sterile supernatant was used to perform PCR against kanamycin cassette specific primers 
(Table 3). Genomic DNA isolated from wild-type BCG and pSD5.hsp60 shuttle vector 
were used as controls.  
7. Quantitative real-time PCR (qPCR) for M.tb disA: 
Late log phase BCG cultures were harvested and bead beating was carried out using 
zirconium beads (Cat. KT03961-1-102.BK, Berlin Technologies) before performing total 
RNA isolation using Trizol method (Cat. 15596026, Fischer Scientific) as suggested by 
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manufacturer. The quality and quantity of RNA was determined using DNA gel analyses 
and Nanodrop. Quantification of mRNA, amplification, and quantification of cDNA was 
carried out using SYBR Fast green double stranded DNA binding dye (Cat. 4085612, 
Applied Biosystems, USA) and ABI StepOnePlus Real Time PCR System (Applied 
Biosystems, USA). Amplification of M.tb sigH (Table 3) was carried out as an internal 
control. PCR was performed at 95 °C, 2 minutes, followed by 40 cycles of 95 °C, 5 seconds; 
60 °C, 30 seconds. Melt curve analyses confirmed formation of desired and specific PCR 
product. Experiments were performed in triplicate using three independent biological 
samples and results were analyzed and presented using 2-∆∆CT method (25730264). Details 
of NCBI gene identifiers and primer sequences are mentioned (Table 3).  
8. Mammalian Cell Culture:  
THP-1, an acute monocytic leukemia-derived human cell line (ATCC, TIB-202TM) was 
cultivated in suspension at a density 105 to 106 cells/mL in RPMI-Glutamax (Cat. 61870-
036, Fischer Scientific) and supplemented with 10% heat inactivated fetal bovine serum 
(Cat. 10082147, Fischer Scientific) with 1% streptomycin/penicillin at 37°C with 5% CO2. 
For differentiation, cells were treated with 50 ng/mL phorbol 12-myristate 13-acetate 
(Sigma-Aldrich, P1585) for 48 hours to induce differentiation into macrophages. For 
activation, THP-1 cells were treated with 100U/ml human recombinant interferon gamma 
(Cat. 300-02, Peprotech) for 6 hours.   
J774A.1 (ATCC® TIB67™) murine macrophage cell line was cultivated as monolayer in 
RPMI-Glutamax (Cat. 61870-036, Fischer Scientific) supplemented with 10% heat 
inactivated fetal bovine serum (Cat. 10082-147, Fischer Scientific) with 1% 
streptomycin/penicillin (Cat. 15140-122, Fischer Scientific) at 37°C with 5% CO2. For 
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infection assays cells were seeded at desired density for 3 hours for attachment on surface. 
For activation of J774A.1 cells were treated with 100U/ml mouse recombinant interferon 
gamma (315-05, Peprotech) for 6 hours. 
Mouse bone marrow derived macrophages (Mouse BMDM): 
 Murine bone marrow was isolated from 4-6 weeks old female C57BL/6J (Charles river). 
Approximately 108 cells were stored in cryomedia (10% DMSO in heat inactivated FBS) 
overnight at -80°C followed by transfer to deep cryopreservation in liquid nitrogen. For 
differentiation of bone marrow cells into primary macrophages, bone marrow cells were 
differentiated for 7 days in presence of RPMI-Glutamax supplemented with 10% heat 
inactivated fetal bovine serum and antibiotics (Penicillin-Streptomycin solution) and 30% 
(vol/vol) L929 conditioned media. Mouse fibroblast L929 cells (ATCC® CCL-1™) were 
maintained in RPMI-1640 medium supplemented with 10% FBS and antibiotics. 
Human and Rat bladder cell lines:   
Human epithelial grade II carcinoma from bladder tissue 5637 was (ATCC® HTB-9™), 
Human transitional cell papilloma RT4 (ATCC ® HTB-β™) and N-butyl-N-(4-
hydroxybutyl) nitrosamine induced tumor cell line in Rattus norvegicus Nara Bladder 
Tumor No. 2 (ATCC® CRL-1655™) were maintained in RPMI-1640 medium 
supplemented with 10% FBS and antibiotics was cultured and used as monolayer at 37°C 
and 5% CO2.  For infection assays cells were seeded at desired density for 3 hours for 
attachment on surface.  
9. In vitro infection assays:  
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For infection assays, macrophages were seeded at desired cell density as mentioned earlier 
[61].  Briefly, log phase bacterial cultures were repeatedly washed with phosphate buffered 
saline (PBS) (Cat. 14190144, Life Technologies, USA) to remove any trace of detergents, 
infection was carried out at 1:20 multiplicity of infection (M.O.I.). Infection was allowed 
in macrophage infection media (RPMI-1640 with 10% FBS) for 5 hours. Non-infective 
extracellular bacilli were removed by repeated washing using PBS. This time point was 
considered 0 hours, and cells were subsequently incubated for different time points till the 
end-point was achieved.  
10. Quantitative real time PCR for Human, Mouse and Rat genes:  
Gene expression profiling in human (Homo sapiens), mouse (Mus musculus) and rats 
(Rattus norvegicus) were carried using different RNA samples originating from primary 
macrophages (mouse BMDMs), macrophage cell lines (THP-1 and J774.1), and different 
bladder cancer cell lines (RT4, 5637 and NBT-II) after infection assay or drug treatment. 
Briefly, Trizol reagent (Cat no. 15596026, Thermo Fischer Scientific) was used for RNA 
isolation after cells were harvested and quantification of mRNA, amplification, and 
quantification of cDNA was carried out using SYBR Fast green double stranded DNA 
binding dye (Cat. 4085612, Applied Biosystems, USA) and ABI StepOnePlus Real Time 
PCR System (Applied Biosystems, USA) as mentioned earlier (25730264). Amplification 
of RNU6A (for Human genes), and -actin (for Mouse and Rat genes) was used as internal 
control. Experiments were performed in triplicate using three independent biological 
samples and results were analyzed and presented using 2-∆∆CT method [61]. Details of 
NCBI gene identifiers and primer sequences are given in the Table 3.   
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11. Measurement of IRF activation:  
RAW-Blue ISG (InvivoGen) reporter cells were derived from the murine RAW 264.7 
macrophage cell line by stably integrating an interferon regulatory factor (IRF)-inducible 
secreted embryonic alkaline phosphatase (SEAP) reporter construct (QUANTI-Blue™, 
Invivogen). The cells were infected with wild-type and disA OE strains with a pre-
calibrated MOIs for 6 hours. Non-infective, extracellular bacilli were removed by repeated 
washing using PBS. Cells were incubated for another 18 hours in fresh macrophage 
infection media (DMEM without antibiotics), and culture supernatants were harvested for 
determination of IRF activation by a SEAP colorimetric assay using QUANTI-Blue 
reagent.  
12. Cytokine profile using ELISA:  
Following in vitro infection, culture supernatants were used to perform cytokine ELISA. 
Briefly, mouse DuoSet ELISA kits (R and D systems, USA) for TNF (Cat. DY410), IL-6 
(Cat. DY406-05) and IL-1  (Cat no. 401).  Human DuoSet ELISA kits (R and D systems, 
USA) for TNF (Cat. DY410), IL-6 (Cat. DY206-05), IL-1  (Cat. DYβ01-05) and MCP-
1(DY279-05) were used to quantify the cytokines. The absolute concentrations were 
determined by referring to a standard curve and expressed as pg/mL as described earlier 
[61]. For quantification experiments were performed in triplicates. 
13. In vivo Rat model of bladder cancer:  
We have used an immune competent Fisher rat model of bladder cancer that was 
established at Department of Urology, Johns Hopkins Hospital in collaboration with the 
Bivalacqua laboratory. This is a proven animal model of bladder cancer and has been used 
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to test the therapeutic outcomes on bladder tumor after instillation with BCG [79]. For In 
vivo instillation of wild-type and BCG-disA OE Pasteur strains, all protocols involving 
animals followed US National Institutes of Health guidelines and were approved by the 
animal and care use committee of the Johns Hopkins Medical Institutions as discussed 
elsewhere [79].   
MNU instillation and tumor induction: 
For tumor induction, 7- week old Fischer 344 females (avg. weight 160g) were placed with 
free access to food and water in 12 hours light/dark lighting cycle. N-Nitroso-N-methylurea 
(MNU), an alkylating agent that is a potent mutagen and cancer-causing agent was directly 
deposited into the urinary bladder of the rats for tumor induction. Briefly, 3% isoflurane 
was used for anesthesia, 20G angiocatheter (BD) was placed into the urethra and 300 µl of 
MNU (1.5 mg/kg) was instilled in the bladder as discussed earlier. A total of 4 instillations 
of MNU was given to each rat as described earlier and animals were monitored using serial 
bladder ultrasound at 8 weeks following MNU instillation using the 2100 Visual sonic 
ultrasound system (Toronto, Ontario, Canada). In order to access the immunological 
correlates, the immune profile of the MNU model itself, representative animals were 
sacrificed at 8 and 16 weeks after MNU instillation [79]. 
BCG instillation and Tissue Harvest: For testing the effect of BCG instillation on bladder 
tumor, rats were given intravesical administration of 108 CFU in a total volume of 300 µl 
via a 20G angiocatheter per week for a total of six dosages as described earlier [79]. 
Treatment groups included wild-type and disA OE strains of BCG Pasteur. Animals were 
sacrificed at week 16, bladders were collected for histopathological analyses (n = 5/group), 
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and areas of cancerous epithelium urothelium were snap frozen for measurement of 
cytokines and chemokines as described earlier. 
14. Immune profiling of BCG treated Rat Bladders: 
For gene expression profiling of immunological effectors, areas of cancerous bladder 
urothelium were identified, dissected, excised and frozen for RNA isolation. Control 
bladder from normal rat and MNU instilled control rats were also taken out. RNA isolation 
was performed using Trizol method. Quantification of mRNA, amplification, and 
quantification of cDNA was carried out using SYBR Fast green double stranded DNA 
binding dye (Cat. 4085612, Applied Biosystems, USA) and ABI StepOnePlus Real Time 
PCR System (Applied Biosystems, USA) as mentioned earlier [61]. Amplification of -
actin was used as internal control. Experiments were performed using 5 different biological 
samples (n=5) and results were analyzed and presented using 2-∆∆CT method. Details of 
NCBI gene identifiers, primer sequences and PCR product sizes are given in the Table 3. 
15. Histologic analyses:  
For histological analyses, whole bladders were formalin fixed and paraffin embedded. 
Sections were prepared and stained using hematoxylin-eosin staining as described earlier 
[79]. A board certified genitourinary pathologist performed the tumor staging in a blinded 
manner as mentioned previously [79]. Specimens were placed into bins based on the 
percentage of involvement of abnormal tissue (1=10% involvement, 2=20% involvement 
and so forth).  
16. Statistical analyses:  
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Fold-expression (qRT-PCR and ELISA) was represented as the mean of 3 independent 
experiments ± standard error mean (SEM). Student’s T test (*P < 0.05 **P < 0.01, ***P < 
0.001). MOI (multiplicity of infection). 
 
Table 3. List of primer sequences used for gene expression analysis 
Accession 
Number 
Gene Primer Sequence 5'-3' 
- pSD5hsp60.MT3692 (F) GGGCATCATATGCACGCTGTGACTCGTC 
pSD5hsp60.MT3692 (R) GGGACGCGTTATTGATCGCTGATGGTCGA
TT 
- Kanamycin cassette (F) GAGAAAACTCACCGAGGCAG  
Kanamycin cassette (R) GTATTTCGTCTCGCTCAGGC  
32287254 sigH (F) GCGATGGTGGCTTCTCCCTCG 
sigH (R) CCATCTTGCACAGCTCGCGTAG 
11461 Mouse.  actin (F) TAAGGCCAACCGTGAAAAGATG 
Mouse.  actin (R) CTGGATGGCTACGTACATGGCT 
 21926 Mouse.TNF-α (F) GACCCTCACACTCAGATCATC 
Mouse.TNF-α (R) GCTGCTCCTCCACTTGGT 
15977 Mouse.IFN  (F) CCACAGCCCTCTCCATCAAC 
Mouse.IFN  (R) CTCCGTCATCTCCATAGGGA 
16193 Mouse.IL6 (F) CTGCAAGAGACTTCCATCCAG 
Mouse.IL6 (R) CAGGTCTGTTGGGAGTGG 
16193 Mouse.IL-2 (F) CCTGAGCAGGATGGAGAATTACAG 
Mouse.IL-2 (R) CAATTCTGTGGCCTGCTTGGG 
26827 Human. RNU6A (F) CTCGCTTCGGCAGCACATATAC 
Human. RNU6A (R) AATATGGAACGCTTCACGAATTTG 
3456 Human.IFN  (F) CAACTTGCTTGGATTCCTACAAAG 
Human.IFN  (R) TATTCAAGCCTCCCATTCAATTG 
3569 Human.IL6 (F) GGTACATCCTCGACGGCATCT 
Human.IL6 (R) GT GCCTCTTTGCTGCTTTCAC 
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6347 Human.MCP-1 (F) GTGCTGACCC-CAATAAGGAA 
Human.MCP-1 (R) TGAGGTGGTTGTGGAAAAGA 
4843 Human.iNOS (F) TGCAGACACGTGCGTTACTCC 
Human. iNOS (R) GGTAGCCAGCATAGCGGATG 
3586 Human.IL-10 (F) GCTCCTGAGGTATGGAATAGAGTCC 
Human.IL-10 (R) TATGTGTCATTTGCGGGGGC 
64367 Rat.PPIB (F) CAGGATTCATGTGCCAGGGT 
Rat.PPIB (R) CCAAAGACCACATGCTTGCC 
24481 Rat.IFN-  (F) GAGTCTTCACACTCCTGGC 
Rat.IFN-  (R) GTCCTTCAGGCATGAGACAG 
298210 Rat.IFN-α (F) GCGTTCCTGCTGTGCTTCTC 
Rat.IFN-α (R) CCATTCAGCTGCCTCAGGAGC 
25712 Rat.IFN-  (F) CGTCTTGGTTTTGCAGCTCT 
Rat.IFN-  (R) CGTCCTTTTGCCAGTTCCTC 
24599 Rat. iNOS (F) GGTGAGGGGACTGGACTTTTAG 
Rat. iNOS (R) TTGTTGGGCTGGGAATAGCA 
245920 Rat.IP10 (F) TCCACCTCCCTTTACCCAGT 
Rat.IP10 (R) AGAGCTAGGAGAGCCGTCAT 
24770 Rat.MCP-1 (F) CAGGTCTCTGTCACGCTTCTG 
Rat.MCP-1 (R) GCCAGTGAATGAGTAGCAGCAG 
25542 Rat.MIP-1α (F) ACAAGCGCACCCTCTGTTAC 
Rat.MIP-1α (R) GGTCAGGAAAATGACACCCG 
116562 Rat.IL-2 (F) CTGCAGCGTGTGTTGGATTT 
Rat.IL-2 (R) GGCTCATCATCGAATTGGCAC 
24494 Rat.IL-1  (F) GACTTCACCATGGAACCCGT 
Rat.IL-1  (R) GGAGACTGCCCATTCTCGAC 
24835 Rat.TNF-α (F) CGTCCCTCTCATACACTGG 
Rat.TNF-α(R) CATGCTTTCCGTGCTCATG 
59086 Rat.TGF-  (F) TGACGTCACTGGAGTTGTCC 
Rat.TGF-  (R) CCTCGACGTTTGGGACTGAT 
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25325 Rat.IL-10 (F) CCTCTGGATACAGCTGCGAC 
Rat.IL-10 (R) TGCCGGGTGGTTCAATTTTTC 
24498 Rat.IL-6 (F) GCGATGATGCACTGTCAG 
 Rat.IL-6 (R) GAACTCCAGAAGACCAGAGC 




Table 4.  Plasmids and Bacterial strains used in the study 
Name  Description  
Plasmids  
pSD5.hsp60  Mycobacterial expression plasmid with hsp60 promoter  
pSD5hsp60.MT3692  disA over-expression plasmid  
M. bovis BCG strains  
BCG  M. bovis BCG Pasteur  














Generation of recombinant BCG overexpressing c-di-AMP 
 
3.1 Introduction 
Detection of invading pathogens by specific pathogen associated molecular patterns 
(PAMPs) by pattern recognition receptor (PRRs) is one of the earliest firewalls of the 
innate immune system. Initial encounter of M.tb by alveolar macrophages or dendritic cells 
initiates a series of innate immune responses. Diverse classes of germline-encoded PRRs 
associated with myeloid cells include toll like receptors such as TLR2 and TLR9, C-type 
lectin receptors, mannose receptors, scavenger receptors, NOD2 and NLRP3. NOD-like 
receptor family, AIM-2 like receptors (absence in myeloma, ALRs), cyclic GMP-AMP 
synthase (cGAS) and stimulator of IFN genes (STING), recognize specific PAMPs and 
thus promote activation of NF-κB, and type I interferon (IFN) responses and several 
downstream signaling networks. Downstream effects of activation of IRF-3 and NF-κB, 
lead to the transcription of innate effector molecules, including IFN , TNF, IFN , and IL1  
[32,80]. These innate effector molecules are responsible for execution of a variety of 
antimicrobial effects, ranging from activation of cell death, such as apoptosis and 
autophagy in immune and stromal cells [81-83]. 
Previous studies from Bishai Laboratory showed that M.tb encodes di-adenylate cyclase 
enzyme, disA (MT3692) and can synthesize and secrete c-di-AMP. It was also 
demonstrated that c-di-AMP production and secretion was increased by over-expressing 
disA under a strong mycobacterial promoter, hsp60 [65,84]. Over-production of c-di-AMP 
allowed activation of the interferon regulatory factor (IRF) pathway and Type 1 IFN 
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responses through the (STING)-signaling pathway [85]. We wanted to test the therapeutic 
potential of wild-type vs recombinant BCG in a rat model of bladder cancer [79]. We 
hypothesize, that the BCG-disA OE strain due to its ability to activate STING-mediated 
Type I IFN responses will be more efficacious to conventional wild type BCG strain. 
We decided to make changes to the genome of BCG Pasteur strain to improve its ability to 
overexpress c-di-AMP. We used similar strategy of overexpressing c-di-AMP that was 
employed earlier using M.tb strain as reported earlier [61]. Recombinant strains encoding 
and overexpressing M.tb-disA (MT3692) (BCG-disA OE) under strong bacterial promoter 
showed a robust increase in disA levels as compared to their wild-type parental control. 
Using In vitro infection experiments with murine reporter cell lines and primary bone 
marrow-derived macrophages (mBMDM) we found BCG-disA OE induced IRF activation 
coupled with augmented levels of IFN . We believe these strains could act like potential 
STING agonists and anti-tumor immunotherapeutic agents. 
3.2 Results 
3.2.1 Generation of recombinant BCG strain overexpressing disA (BCG-disA OE): 
We generated a recombinant BCG strains (BCG-disA OE) overexpressing the endogenous 
di-adenylate cyclase (disA) encoded by gene MT3692 in the CDC1551 strain that facilitates 
c-di-AMP generation from ATP or ADP. MT3692 was cloned under strong promoter hsp60 
and clones were confirmed using insert release followed by sequence analyses (Figure 1a 
and 1b). Recombinant clones were selected against kanamycin (25 µg/mL) using 7H11 
plates. Single isolated colonies were picked and inoculated in the 7H9 media containing 
kanamycin (25 µg/mL). Recombinant strains were confirmed for the presence of 
kanamycin cassette (antibiotic selection marker) using colony PCR (Figure 1c). All clones, 
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except wild type BCG were positive for Kanamycin resistance (Figure 1c). Clones positive 
for the antibiotic selection marker were screened for disA overexpression phenotype using 
quantitative real-time PCR. Gene expression profiling showed ~50-fold upregulation of 
disA expression in BCG-disA OE as compared to their wild-type parental control (Figure 
2).  
3.2.2 Recombinant BCG overexpressing c-di-AMP results in IRF induction and IFN-
β gene expression:  
We next wanted to determine if the robust induction of disA expression in BCG-disA OE 
would result in c-di-AMP mediated induction of IRF3 and IFN  as demonstrated 
previously [61]. Raw Blue™ ISG reporter macrophage cells were infected with wild-type 
and BCG-disA OE strains and the levels of secreted alkaline phosphatase (SEAP) was 
measured in the supernatant using QUANTI-Blue™. A β-fold induction of IRF was 
observed in cells infected BCG-disA OE as compared to the wild-type control (Figure 3). 
Polyinosinic-polycytidylic acid or Poly (I:C) a synthetic analogue of double stranded RNA 
(dsRNA) and a molecular motif known to activate IRF3, was used a positive inducer of 
IRF in this assay [86]. Poly (I:C) mediated a strong induction of IRF in the assay (Figure 
3). These results provide strong evidence that BCG-disA OE was producing heightened 
levels of c-di-AMP and activating of IRF in this reporter cell line. Next, we wanted to test 
the if BCG-disA OE could activate primary murine macrophages. Primary murine BMDMs 
were challenged with to wild-type BCG and BCG-disA OE strains for different time points 
and Ifnb induction was quantified using qPCR. A modest but significant induction of Ifnb 
was observed as early as 6 hours in BMDMs infected with BCG-disA OE as compared to 
wild-type BCG (Figure 4).  
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3.3 Discussion  
Gene regulation in response to external stimuli and modification of cellular processes is 
enabled in organisms by signal transduction pathways, including CSPs.  Second messenger 
moieties, such as cyclic di-nucleotides (CDNs) play prominent roles in growth, 
differentiation, and cellular stress responses in prokaryotes, including pathogenic insults 
and inflammation in metazoans [87]. 
Some of the key cyclic nucleotides such as, cyclic adenosine monophosphate (c-AMP), 
cyclic guanosine monophosphate (c-GMP), cyclic di-guanosine monophosphate (c-di-
GMP), and cyclic di-adenosine monophosphate (c-di-AMP) can be classified as canonical 
as well as non-canonical CDNs. β’-5’ and γ’-5’ cGMP-AMP are the natural products of 
cGAS (β’γ’ cGAMP) that have STING binding affinity owing to their mixed linkages and 
are referred to as non-canonical CDNs, while the CDNs associated with bacteria usually 
have canonical γ’-5’ linkages [88]. 
Previously, our laboratory has shown that M.tb genome encodes a di-adenylate cyclase 
enzyme (disA or dacA, MT3692 in CDC 1551) that is involved in c-di-AMP synthesis. It 
was also shown that macrophages infected with M.tb strains overexpressing disA were 
activated by the bacterial-derived c-di-AMP resulting in the strong induction of IFN  levels 
[61]. Since, c-di-AMP acted as a PAMP [80], this study was critical for understanding 
STING-mediated  IRF and IFN  induction. It was also found that increased levels of IFN  
was independent of interaction of c-di-AMP with cytosolic nucleic acid receptor cyclic-
GMP-AMP (cGAMP) synthase (cGAS) [61]. 
Woodward et al. showed that bacterial infection of nonphagocytic cells leads to cytosolic 
penetration by leaky CDNs and that results in IFN induction [60]. Similarly, several studies 
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using intracellular pathogens such as Chlamydia and Listeria suggested STING-dependent 
induction of type I IFNs, that were dependent of CDNs greatly influenced virulence and 
intracellular survival in host cell niches [35, 60]. Orthologues of disA exist in all 
mycobacterial genomes except for M. leprae. The notion that CDNs can induce STING-
dependent, but cGAS independent induction of type I IFNs (even in absence of 
extracellular pathogenic DNA) was validated by Dey et al., when they demonstrated that 
disA overexpressing strains of BCG were shown to induce a stronger Type I IFNs [61]. 
Since BCG strains lack the RD-1 locus or the Esx-1 secretion system required to release 
bacterial DNA, among other virulence factors, it was hypothesized that bacterial c-di-AMP 
was sensed by the macrophages leading to STING-dependent IFN  synthesis. Additional 
experiments will be required to prove if BCG secretes c-di-AMP inside macrophages and 
exclude the possibility that cells are being activated because of dying bacilli and/or the leak 
of bacterial DNA from phagocytic vesicles. 
Extracellular DNA of pathogenic bacteria and viruses (dsDNA) act as potent inducers of 
IFN α/  in infected macrophages [89]. The bacterial and viral nucleic acids are recognized 
by cytosolic cGAS for generation of cGAMP that in turn, bind and activate STING that 
subsequently phosphorylates adaptor protein TBK1. TBK1 phosphorylates IRF3 and 
initiates the transcription of several interferon stimulated genes (ISGs), including Ifna, Ifnb 
and other co-activated transcription factors, including the NF-kB and STAT6 [49, 90]. 
Previous studies with disA overexpressor strains of M.tb reported a strong co-activation of 
TNF, IL-6 and IL-1  in infected macrophages suggesting a possible cross-talk among 
different immune signaling pathways [65]. 
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Our preliminary data with disA overexpressing strains suggested increased Type I IFN 
responses, a phenotype that was earlier reported in M.tb. This finding was first step towards 



































Figure 1. Generation and confirmation of BCG Pasteur strain overexpressing disA. 
(A) The disA gene of M. tuberculosis, MT3692, which shows 100% homology with BCG 
disA gene was PCR purified from M.tb CDC 1551 genomic DNA using gene specific 
primers. (B) Gene amplicons and pSD5 vectors were separately digested using same set of 
restriction enzymes and were ligated at the NdeI and MluI restriction sites. This resulting 
ligated construct of pSd5.hsp60.MT3692 plasmid was used to transform BCG Pasteur 
strain and the recombinant clones were selected against Kanamycin (β5 μg/mL). (C) 
Colony PCR using Kanamycin gene specific primers confirmed the presence of the 







Figure 2. Overexpression of disA in BCG-disA OE strain:Quantitative real time PCR of 
BCG-Pasteur and BCG-disA OE strains for the disA gene (MT3692). For qPCR, total RNA 
was extracted from log phase BCG cultures, cDNA was prepared using SuperScript™ III 
First-Strand Synthesis. qPCR was performed using Applied Biosystems ABI StepOnePlus 
system. The expression was normalized first to the internal control (sigH) and then to wild-
type BCG Pasteur. The graphical points represent mean of three independent experiments 


















Figure 3. BCG overexpressing disA augments IRF3: Effect of disA overexpression on 
activation of IRF pathway measured by IRF-SEAP QUANTI Blue reporter assay. Mouse 
BMDMs were challenged with wild-type and BCG-disA OE strains at an MOI of 1:20 for 
5 hours to establish the infection. Uninfected bacteria were washed out using ice-cold PBS 
and subsequently incubated for another 18 hours. The culture supernatants of infected 
RAW-Blue ISG cells were assayed for IRF activation. The image below the IRF-activation 
graph represents QUANTI Blue assay plate and sample wells; treatment parameters for 
column of wells correspond to those defined for the bars above aligned with the wells. The 
graphical points represent mean of three independent experiments ± standard error mean 











Figure 4. Differential expression of Ifnb: Mouse BMDMs were challenged with wild-
type and BCG-disA OE strains at an MOI of 1:20 for 5 hours to establish the infection. 
Uninfected bacteria were washed using ice-cold PBS and cells were subsequently 
incubated for another 6 hours. Expression levels of mRNA was measured using a SYBR 
green-based quantitative real-time PCR. Basal level of transcript (mRNA) in untreated 
macrophages was used for data normalization and hence to access relative expression. �-
actin was used as an internal control. Data analysis was performed using 2−∆∆CT method. 
The graphical points represent mean of 3 independent experiments ± standard error mean 








In Vitro Immune Profiling in Macrophages against BCG-disA 
OE 
 
4.1 Introduction:  
STING was discovered by Glen Barber and colleagues as a MyD88-independent host cell 
defense factor expressed in macrophages, dendritic cells (DCs) and fibroblasts that induced 
expression of type I interferon-dependent and NF-κB dependent pro-inflammatory 
cytokines in response to cytoplasmic DNA [70,91]. Subsequently several additional DNA 
sensors were identified, such as Sox2, AIM2, DAI, IFI16 and DDX41, that can detect 
microbial DNA and induce innate immune responses, however, the cyclic GMP-AMP 
(cGAMP) synthase cGAS is considered the main sensor of cytosolic DNA [70,72,92-97]. 
Activation of cGAS/STING axis after recognition for foreign DNA leads to recruitment 
and activation of the kinase TBK1, which phosphorylates IRF3 and increases Type I IFN 
production. STING can also cross-talk with other transcription factors that are critical for 
synthesis of several cytokines and chemokines [49,90,97]. NF-kB, a heterodimeric 
transcription factor, and a key player of inflammatory and immune responses, is maintained 
inside the cytoplasm through its interaction with the inhibitory protein I kappa-B alpha 
(IκBα). Upon cytokine stimulation, a multi-subunit protein kinase, the I kappa B kinase 
(IKK), is rapidly activated and phosphorylates two key serine residues in the N-terminal 
regulatory domain of the IκBα, that results in the separation of the NF-kB dimer and 
degradation of IκBα by the proteasome. The Rel A/p50 NF-kB dimer then translocates to 
the cell nucleus and mediates inflammatory responses [99]. STING can also directly 
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activate Iκκ, which in in turn phosphorylates the inhibitor IκBα to release NF-κB and 
influence gene transcription of pro-inflammatory cytokines [100]. Although, the binding 
affinity of c-di-AMP for STING is far weaker than cGAMP, ligation of c-di-AMP to 
STING appears sufficient to induce co-activation of transcription factors other than IRF3 
and hence induce pro-inflammatory signatures [58,101]. Identification of another bona-
fide physiological sensors for c-di-AMP, an endoplasmic adaptor, ERAdP, that binds to c-
di-AMP with high affinity, results in initiation of activation of NF-κB signaling in innate 
immune cells to induce the production of pro-inflammatory cytokines during bacterial 
infection indicating a rather complex link between c-di-AMP-based STING activation and 
induction of Type I IFN and pro-inflammatory cytokines [102]. Nevertheless, direct 
activation of NF-kB by cGAS/STING/TBK1 axis is sufficient to explain induced levels of 
proinflammatory cytokines along with interferon α/  in immune cells due to increased 
levels of canonical or non-canonical CDNs  [101,103-105]. 
M.tb strains engineered to overexpress disA induce several key pro-inflammatory 
cytokines, including IL-6, TNF and IL-1 . We used gene expression and cytokine secretion 
to determine the immune profiles, characteristic macrophages infected with wild-type or 
BCG-disA OE. Previously, we demonstrated that BCG-disA OE strain increased IRF3 
induction of and Ifnb expression in macrophages when compared to the wild type control 
BCG (Chapter 3, Figure 4) In addition, we profiled immune responses in macrophage cell 
lines and primary macrophages at the transcript as well as the protein level using qPCR 
and ELISA, respectively. In the work presented in this chapter, immune profiling using 
qPCR assay showed a distinct initial wave of STING-induced effector molecules (cytokine 
and chemokine) in macrophages infected with BCG-disA OE. ELISA results corroborated 
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gene expression profile suggesting true biological modulation of immune effectors. We 
found increased expression of key Th1 (IFNy and IL-2) and M1 cytokine (TNF and IL-6) 
in macrophages infected with BCG-disA OE strain, as early as 3 hours after infection. A 
potent increased in cytokines (TNF, IL-6 and IL-1 ) and chemokines (MCP-1) were also 
observed in macrophages infected with BCG-disA OE of BCG. This in vitro immune 
profiling strategy to identify the characteristic immune responses in macrophages in 
response to increased level of intracellular c-di-AMP suggested that the CDN c-di-AMP 
potently activates the CSP of macrophages. Also, these results suggest that BCG-disA OE 
strain functions as a potent STING agonist and has potential as a potential 
immunotherapeutic tool against certain forms of cancer. 
4.2 Results:  
4.2.1 Immune profiling of macrophages infected with wild-type or BCG-disA OE: We 
challenged C57BL/6J BMDMs with wild-type BCG or BCG-disA OE strain to identify 
differential gene expression profile of key cytokines at an early temporal window. Since 
we expected a rapid and change in macrophage environment in response to enhanced disA 
transcription and c-di-AMP production, an early time point was selected for gene 
expression profiling. A rapid nuclear translocation of RelA/p50 subunits and hence 
induction of gene expression is a hallmark of NF-κB signaling during pathogenic insult. 
Uninfected macrophages were considered controls for basal level gene expression, while 
macrophages infected with wild type BCG were considered the infection control to 
determine because the impact of disA overexpression. We found increased abundance in 
the number of transcripts for the genes encoding TNF, IL-6 and IL-2 as early as 5 hours 
after the macrophages were infected with BCG-disA OE compared to the wild-type BCG 
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(Figure 5). Increases in TNF-α and IL-6 have been previously reported in macrophage 
infected with M.tb disA OE infected macrophages as compared to those infected with wild-
type parental controls [77]. The differential induction of Th1 (IL-2) and M1 (TNF and IL-
6) cytokines have been hypothesized as direct consequence of coactivation of NF-κB, and 
STAT6 transcription that follows or parallels IRF3 activation in response to CDNs [49]. 
We next ascertained the translatability of gene expression profile by performing 
ELISA using the culture supernatants from macrophages infected with wild-type or BCG-
disA OE strains of BCG. Two different cell types namely, mBMDM and human THP-1 
cells were used perform in vitro cytokine ELISA. Resting mBMDMs were challenged with 
wild type and BCG-disA OE strains, culture supernatants were harvested at 24 hours and 
were quantified using ELISA based assessment of cytokine production. We found 
significantly increased levels of TNF, IL-6 and IL-1  in murine BMDMs infected with 
BCG-disA OE strains as compared to those infected with wild-type parental BCG (Figure 
6) suggesting macrophage polarization towards M1 phenotype. This immune activation 
phenotypes observed in mouse-derived cells was also seen in human derived, PMA 
differentiated, IFN-  activated THP-1 cells. Increased levels of IL-6, MCP-1 and IL-1  in 
response of disA overexpression (Figure 7) clearly suggested a coactivation NF-κB and 
STAT6 that has been proposed once STING is activated by CDNs [90,106]. STAT6 plays 
a prominent role in adaptive immunity by transducing signals from extracellular cytokines. 
DNA viruses are known to induce STING and recruit STAT6 at the endoplasmic reticulum 
(ER) site leading to phosphorylation of specific Serine residues at STAT6 by TBK1, that 
is independent of JAKs [90,107]. This mechanism is crucial for nuclear translocation of 
STAT6 and transcription of specific target genes responsible for immune cell (monocytes, 
40 
 
macrophages and T cells) homing, most importantly MCP-1 [90,108-109]. Recent studies 
by Lalita Ramakrishnan’s group showed PGL-1 dependent STING activation is 
responsible for MCP-1 or CCL2 secretion in human alveolar macrophages [110]. CCL2 is 
important for recruitment of inflammatory monocytes to areas of inflammation and acts 
like a bridge between innate and adaptive immunity. We tested the differential modulation 
pattern of MCP-1/CCL2 in human macrophages and found a strong induction of CCL2 in 
culture supernatants of macrophages infected with disA OE infected macrophages (Figure 
7)  
4.3 Discussion:  
Canonical and non-canonical cyclic di-nucleotides (CDNs) are undergoing clinical testing 
to determine their ability to activate STING/TBK1/IRF3 axis and generate a strong anti-
tumor response (Table 1). This new class of STING agonists have proven efficacious in in 
vivo models of non-immunogenic and immunogenic tumors [35-36]. Treatment of NMIBC 
bladder cancer is based on BCG-mediated cancer immunotherapy and STING agonists 
have also been tried using different models to prove their effectiveness [111, 112]. Our aim 
was to generate a BCG strain that not only carries the immune-dominant epitopes of 
mycobacteria but also selectively activates STING-dependent anticancer Type I 
interferons.  Although we found increased IFN , we also found increased pro-
inflammatory cytokine such as TNF, IL-6 and IL-1 , suggesting a possible augmentation 
of NF-κB and STAT signaling that is a result of co-activation either through autocrine or 
paracrine mechanisms.  
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BCG strains lack the Esx-1 secretion system and hence BCG is thought to be unable 
to release bacterial DNA inside macrophages [89]. Recently these models of ESAT-6-
dependent changes in vacuolar phagosome has been challenged [65]. M.tb containing 
phagosomes are considered a dynamic and relatively leaky structure that can facilitate 
communication between macrophage cytosol and phagosome harboring bugs. Other 
studies suggest leakage of c-di-nucleotides (CDNs) in adjacent cells through gap junction, 
a mechanism responsible for induction of pathogen-specific IFNα/  secretion that provides 
immunity to the invading pathogens [60]. We generated a recombinant BCG strain that 
caused strong induction of M.tb disA (Figure 2, Chapter3), activated IRF induction and 
IFN  in murine macrophages. Whether induction of IFN  was dependent on STING/TBK-
1 axis and due to increased influx of c-di-AMP inside macrophages remains to be validated 
by direct measurement of c-di-AMP levels inside macrophages. However, we observed 
stronger proinflammatory cytokine signatures that were very much like studies that have 
been performed using STING agonist or by directly inducing increased c-di-AMP levels 
inside macrophages [49]. Our results suggest a secondary effect of STING activation that 
can canonically or non-canonically activate NF-κB and STAT6. These pro-inflammatory 
cytokines can further activate macrophages in an autocrine or paracrine manner [113]. 
Increased levels of CCL2 in culture supernatants derived from BCG-disA OE infected 
macrophages could possibly be due to STAT6 activation. We yet do not know the exact 
mechanism of induction of CCL2 and immune activated phenotype, but, it will be 
interesting to test these phenotypes using cancer models at the site of tumor 
microenvironment (TME). Interestingly, a recent study clearly showed that STING agonist 
(ADU S100) showed antitumor function through activation of key pro-inflammatory 
42 
 
cytokines, including TNF, IL-6, IL-1  and chemokine such as CCLβ/MCP-1 and IP10 at 
the site of drug administration [49]. It is also worth mentioning that these cytokines 
contributed not just by recruiting monocytes and macrophages but also by activating 
stromal cells [49]. Overall, we generated a BCG strain that was a not just a potent inducer 
of Type I IFN but also caused a bias towards pro-inflammatory cytokine production. These 






Figure 5. BCG overexpressing disA expresses pro-inflammatory cytokines in 
BMDMs. Differential expression of genes encoding TNF, IL-6 and IL-2 in mouse BMDMs 
challenged with wild-type and disA overexpression strains of Mycobacterium bovis BCG-
Pasteur. BMDMs were challenged with wild-type and disA OE strains at an MOI of 1:20 
for 5 hours to establish the infection. Uninfected bacteria were washed using ice-cold PBS 
and cells were subsequently incubated for another 6 hours. Expression levels of mRNA 
was measured using a SYBR green-based quantitative real-time PCR. Basal level of 
transcript (mRNA) in untreated macrophages was used for data normalization and hence 
to access relative expression. �-actin was used as an internal control. Data analysis was 
performed using 2−∆∆CT method. The graphical points represent mean of three independent 
experiments ± standard error mean (SEM). Student’s t test (*P < 0.05 **P < 0.01, ***P < 









Figure 6. Increased pro-inflammatory cytokines in response to disA overexpression 
in BMDMs.  Differential expression of TNF (A), IL-6 (B) and IL-1� (C) in mouse 
BMDMs challenged with wild-type and disA overexpression strains of Mycobacterium 
bovis BCG-Pasteur. BMDMs were challenged with wild-type and disA OE strains at an 
MOI of 1:20 for 3 hours to establish the infection. Uninfected bacteria were washed using 
ice-cold PBS and cells were subsequently incubated for another 18 hours. Culture 
supernatants were assayed by ELISA for different cytokines. The graphical points 
represent mean of three independent experiments ± standard error mean (SEM). Student’s 











Figure 7. Increased pro-inflammatory cytokines in response to disA overexpression 
in human THP-1 cells.  Differential expression of IL-6, MCP-1 and IL-1� in PMA-
differentiated THP-1 cells stimulated with IFN-  for 6 h followed by challenge with wild-
type and disA overexpression strains of Mycobacterium bovis BCG-Pasteur. THP-1 cells 
were challenged with wild-type and disA OE strains at an MOI of 1:20 for 5 hours to 
establish the infection. Uninfected bacteria were washed using ice-cold PBS and cells were 
subsequently incubated for another 18 hours. Culture supernatants were assayed by ELISA 
for different cytokines. The graphical points represent mean of three independent 
experiments ± standard error mean (SEM). Student’s t test (*P < 0.05 **P < 0.01, ***P < 







Therapeutic efficacy of BCG-disA OE c-di-AMP 
overexpressing strains and anti-tumor responses in a rat model 
of urothelial carcinoma 
 
5.1 Introduction:  
BCG has remained mainstay of bladder cancer immunotherapy over the last 40 years [114]. 
There is no consensus on a universal mechanism of BCG action, but a complex 
immunomodulation ensues after BCG instillation. BCG attaching to urothelial cells, 
including urothelial carcinoma cells that results in the secretion of an array of pro-
inflammatory cytokines (TNF, IL-6, IL-1  and IL-8) and chemokines (GM-CSF/ CFS2), 
that causes urothelial cell activation [115]. This activation is followed by an influx of 
neutrophils, monocytes, macrophages, lymphocytes, NK cells, and DCs. The infiltrated 
cells become activated and contribute to a variety of additional pro-inflammatory cytokines 
and chemokines [116]. This results in transmigration of large number of neutrophils, T 
cells and macrophages into the bladder lumen where they can be readily measured in the 
patient’s urine. Patients receiving BCG instillation have a transient and massive cytokine 
and chemokine flux that appears in urine that includes elevated IL-1 , IL-2, IL-6, IL-10, 
IL-12, IL-18, IFN , TNF, GM-CSF/CSF2, macrophage colony-stimulating factor (M-
CSF/CSF1), macrophage-derived chemokine (MDC/CCL22), monocyte chemoattractant 
protein 1 (MCP-1/CCL2), macrophage inflammatory-protein-1α (MIP-1α/CCLγ), 
interferon-inducible protein (IP-10/CXCR3/MIG) and eosinophil chemoattractant activity 
(Eotaxin/CCL11) [117-119]. In vitro assays suggest both human and murine macrophages 
47 
 
play tumoricidal roles against bladder cancer cells upon BCG stimulation [120-121]. 
Macrophage mediated killing of bladder cells depends on direct cell to cell contact and 
release of various cytotoxic cytokines such as TNF and IFN  and apoptotic mediators such 
as nitric oxide (NO) as well as direct cytotoxicity mediated by infiltrating lymphocytes 
[55,56,122-124]. Clinical studies reveal that a predominant Th1 cytokine profile (e.g. IFN-
, IL-2, and IL-12) is linked to therapeutic effects of BCG, whereas a high level of Th2 
cytokine such as IL-10 and arginase-1 is linked to BCG failure, suggesting a shift from 
Th2 to Th1 environment for a successful therapy [125-127]. There is a gradual loss of BCG 
induced immune response after the initial treatment, which explain the need for 
maintenance therapy to boost cytokine response and immune infiltration [128]. Also the 
beneficial effect of BCG priming on BCG instillation, is directly linked to improved 
inflammatory responses and recruitment of T cells to the bladder in healthy animals 
compared to a mere BCG single-dose instillation [129]. 
Type I IFN were characterized in late 1970s from the culture supernatants of human 
leucocytes exposed to viruses that was followed by synthesis of IFNαβa and IFNαβb in 
1980s as unmodified recombinant proteins or as their PEGylated versions with improved 
self-life. Interferons were simultaneously approved by various regulatory agencies for the 
treatment of multiple neoplasms [130]. PEGylated IFNαβb has been used for the treatment 
of resected stage II and III melanomas [131]. Type I interferons favor the influx of dendritic 
cells (DCs) and T cells into neoplastic lesions in patient suffering from ulcerated primary 
tumors [132-133]. Despite the beneficial effects of Type I IFN, the treatment is 
accompanied by several undesirable systemic adverse outcomes, and hence, attempts 
began to specifically deliver Type I IFN to the tumor microenvironment [134]. Type I IFNs 
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conjugated to monoclonal antibodies (MAb) such as C22bβb (tetrameric IFNαβb coupled 
to hL243 (a humanized monoclonal antibody that is specific for HLADR), and IFN  fused 
to cetuximab were some of the modifications that were tested against human myeloma and 
EGFR expressing tumors respectively [130,135]. Another approach was generation of 
Type I IFN encoding vectors of various types (e.g. adenoviruses) that were directly injected 
into tumors. An adenovirus encoding IFN-α reduced intratumoral abundance of Tregs and 
promoted accumulation of TH17 cells in CT26 colorectal carcinomas in a mouse model, 
most likely due to increased IL-6 produced by recruited CD11c+DCs [136]. 
Type I IFN in combination with BCG immunotherapy has shown significant anti-
proliferative and immunomodulatory effects than BCG monotherapy itself. Using mouse 
model of bladder cancer, 14/15 mice receiving BCG/IFNα versus 8/15 mice receiving only 
BCG became tumor-free after 5 weekly intralesional treatments [137]. In an interesting 
study, peripheral blood mononuclear cell (PBMC) cultures showed ~66-fold increased 
IFN  production when challenged with BCG plus IFNα compared to BCG alone [115]. 
IFN  is a major Th1-restricted cytokine found in patients responding to BCG 
immunotherapy, it has been routinely used as a surrogate marker for Th1 immune response 
[51]. IFNα itself generates an almost negligible effect on IFN  levels, but BCG-IFNα 
combinatorial treatment, even at lower dosage of BCG was enough to induce increased and 
persistent IFN  levels, along with other pro-inflammatory cytokines (TNF and IL-12) [51]. 
This study supports the idea that adding Th1-stimulating cytokine might reduce dosage of 
BCG immunotherapy and hence associated side effects.  
Type I IFN plus BCG immunotherapy has shown promises for BCG refractory 
patients. The combination therapy appeared safe with a similar side effect profile of BCG 
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alone [138]. In a remarkable study, O’Donnell and colleagues showed that a combination 
therapy administered to 40 patients who failed at least one course of BCG alone, was 
effective to cure 53% patients after 24 months of treatment [139]. There has been a 
concerted effort by the research community to make desirable modifications of BCG that 
can be used as a cocktail of immunotherapeutic cytokines (Table 2, Chapter 1). 
Recombinant BCG strain (rBCG-IFNα) expressing IFNαβb enhanced IFN  expression in 
PBMCs after incubation with rBCG-IFNα as compared to standard BCG, additionally it 
showed increased cytotoxicity in PBMCs as compared to BCG alone most likely due to 
CD56+CD8−NK cells and CD8+ T cells [140]. New developments include generation of 
BCG strains capable of secreting IFNαβb, that cause exuberant immune response and 
cytotoxicity against human bladder cancer cells. Therapeutic benefits of Type I IFN based 
anti-tumor immunotherapy relies on its direct cytotoxicity effects on tumors and its ability 
to promote maturation of dendritic cells (DCs), antigen presentation, and enhance NK or 
CD8+ T-cell mediated antitumor immunity [116]. 
Recently, STING has been proposed to be the key player against immunogenic 
tumors [35,141]. Mice lacking STING experience uncontrolled growth of transplanted 
tumors as compared to their wild-type counterparts. Similarly, STING-deficient mice show 
spontaneous CD8+T cell priming against tumors but not in animals with missing TLRs, 
MyD88 or MAVS adaptor suggesting important role of cytosolic immune surveillance in 
tumor immunity [35]. Tumor-derived DNA is an important player for STING activation, 
Type I IFN production and DC-mediated cross-priming, the immunological events critical 
for generating anti-tumor adaptive immunity [142]. 
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 Since STING activation by tumor-derived DNA appears to play a role in tumor 
growth; targeting STING by using a STING agonist for augmented antitumor response 
appears to be a promising cancer therapy. Several STING agonists are under different 
stages of clinical development (Table 1, Chapter 1) for specific cancer sub-types. Direct 
delivery (intra-tumoral administration) of cyclic dinucleotides (e.g. cGAMP, c-di-GMP, 
and c-di-AMP) into tumor bearing mice has shown substantial growth inhibition of tumors 
due to activation of STING-mediated TBK1/IRF3/IFN axis [49]. Although STING 
agonists are promising antitumor agents, there are challenges, such as development of 
tolerogenic responses and hence increased tumor size due to STING [143]. The leaky 
nature of CDNs (cGAMP can cross cell to cell via gap junctions), is another concern related 
to in vivo application of STING agonists as it might increase pro-inflammatory cytokines 
and promote tumor growth. Still, optimal combination of STING agonists with other 
treatment regimens such as chemotherapy and radiation therapy, and blockade of immune 
checkpoint inhibitors should be developed and tested. 
BCG treatment cures almost 70% of the bladder cancer patients and BCG is a 
promising and effective antigen delivery tool [127]. Several studies corroborate an 
underlying immune response skewed towards Type I IFN and Th1 is associated with a 
positive treatment outcome and hence there is an ongoing effort to develop BCG strains 
that express human Type I cytokines, but till date such efforts have not yielded 
demonstrable improvement over traditional BCG.  Resistance to BCG treatment and 
disease recurrence in a significant proportion of patients with NMIBC prompts the need to 
improve the efficacy of BCG [53-56, 115] 
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Previous studies published from our laboratory showed M.tb strains overexpressing c-di-
AMP can induce excessive IFN  and pro-inflammatory cytokines such as TNF and IL-6. 
We have generated a BCG strain overexpressing bacterial PAMP, c-di-AMP (rBCG-disA 
OE) that generated Type I IFNs in mouse and human macrophages (Chapter 2 and 3). We 
next tested the immune responses elicited by both wild-type and disA OE of BCG in 
different human and rat bladder cancer cells before testing these strains using a relevant in 
vivo animal model of bladder cancer. 
Animals used as a model of bladder cancer can vary from large mammalian animals 
including dogs or monkeys which recapitulate the human disease but have many financial 
and ethical issues associated, to rodents (rats and mice) [146]. Rodents breed well, 
reproduce, less expensive to be maintained and can allow a lot of variation to be studied. 
In reported literature both rats and mice have been equally employed as models of bladder 
cancer.   For example, in carcinogen induced model rats are more frequently used due to 
the advantage of size and possibility of intravesical treatment (specially in MNU induced 
tumors) however in studies requiring the characterize the underlying genetics of the cancer 
mice have been preferred owing to the higher numbers required. Furthermore, in the 
rodents, there is an underlying difference in the pathological and structural characteristics 
of bladder tumor pathogenesis. In rat induced tumors, the tumors are often pedunculated 
and with an inverted papillary growth pattern and characterized as papillary neoplasms 
[147]. While mice usually form more nodular hyperplasia’s which are less frequently seen 
in humans as compared to papillary neoplasms [148]. The rat has been used most frequently 
in these studies to take advantage of the larger body/organ size as in modelling intravesical 
treatment and catheterization [149-150]. Bladder cancers induced in rats also exhibit 
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histopathologic and immunophenotypic features similar to those observed in human 
urothelial cancer. Genetic homology comparisons show that human and rat genes are 90% 
homologous, compared to 80% homology between human and mice genes [149-150]. 
Considering the advantages of using a rat rodent model and orthoptic chemical 
carcinogenic MNU instillations, the Bivalacqua lab pioneered a Fischer rat model for 
NMIBC. In this model, urothelial dysplasia develops within 8 weeks of MNU instillation, 
and by the 16th week after the first instillation, all rats display carcinoma in situ, papillary 
Ta, or high-grade T1 urothelial carcinoma with histopathologic and immunophenotypic 
features similar to those observed in human urothelial cancer [79]. Using this model, the 
Bivalacqua lab showed that intravesical delivery of BCG immunotherapy led to a large, 
transient rise in the CD4+ T cell population in the urothelium  [79]. 
We earlier found that the BCG strain overexpressing c-di-AMP, induced a potent Type 1 
IFN response along with M1 type cytokine in murine and human macrophages. We first 
decided to test the immune responses against BCG-disA OE in different human and rat 
cancer cell lines to define the immune responses in vitro. BCG-disA OE when incubated 
with different stage-specific cell lines showed increased M1 cytokines, and increased IFN 
levels. We next wanted to test the therapeutic potential of BCG-disA OE in the MNU-
induced rodent model of bladder cancer. This was achieved via direct instillation of wild-
type or BCG-disA OE strains to determine the impact of treatment outcome on cancerous 
bladders. By performing an extensive panel of cytokine and chemokine profiling coupled 
with histopathological analyses we demonstrated the relative efficacy of c-di-AMP over 
expressing BCG strains in tumor bearing bladders. Although our results clearly show 
treatment benefits, key questions related to immunological memory responses, 
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contribution of T cell activation, cellular infiltration and expansion and contribution of 
myeloid cells remains to be understood in the in vivo model.  
5.2 Results and Discussions 
5.2.1 BCG-disA OE overexpressing c-di-AMP induces potent Type I IFN coupled with 
enhanced anti-tumor responses in different bladder cancer cells:  
Human transitional cell papilloma RT4 bladder cancer cells, 5637, a human grade II 
carcinoma and NBT-II Rattus norvegicus cell line (derived from a tumor induced with N-
butyl-N-(4-hydroxybutyl) nitrosamine) were used to test immune responses after challenge 
with BCG-disA OE strain and directly compare it with immune responses against wild-
type BCG. Cell lines used here represent different stages of bladder cancer and yield 
information on any notable differences in the physiological response. 
One of the most striking effect of c-di-AMP overexpression was strong induction of Ifnb 
transcription in 5637, RT4 and NBT-II cells as early as 5 hours after BCG exposure (Figure 
8). As previously stated, STING-mediated IFN  induction correlates tumor control and 
anti-tumor milieu in the tumor microenvironment (TME) and increased IFN  levels 
promotes efficient cross-talk between innate and adaptive immunity [134]. These results 
hint that BCG-disA OE is a stronger inducer of anti-tumor type I IFNs.  
We next looked into induction of Th1 cytokines. And found a strong induction of IFN  in 
NBT-II cancer cells (~2-fold as compared to wild-type treated cells) (Figure 11). Earlier 
reports demonstrated that IFN , takes the lead in dictating the cellular anti-tumor response 
and that an increase in IFN  is associated with effective anti-tumor responses [151]. Our 
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in vitro experiments suggested increased IFN , another key anti-tumor cytokine and 
activators of macrophages.  
Macrophages and neutrophils are usually the first cells to accumulate in the bladder 
after BCG instillation in response to the type 1 cytokine environment. Major M1 immune 
effectors cytokines TNF and IL-6 are reported to be induced downstream of STING-
dependent NF-κB activation in myeloid as wells as stromal cells [49]. TNF and IL-6 
showed a modest increase in the carcinogen induced rat bladder cancer cells (NBT-II) 
(Figure 11), while a significant increase in IL-6 was observed in Human grade II carcinoma 
cells (5637) (Figure 10). The increased induction of IL-6 was further corroborated by 
ELISA-based quantification of the secreted cytokine in the culture supernatants 24 hours 
after treatment with BCG strains (Figure 12). There was insignificant change in amount of 
IL-6 in RT4 cell lines (Figure 12), most importantly, we found a very similar 
immunological response in RT4 cells in response to BCG infections as reported elsewhere 
[152-153].Cytotoxic T cells are important in tumor cell killing, an event attributed to T cell 
recruitment (infiltration) that depends on endothelial tumor cells secreting CCL2/MCP-1 
[154]. Human PBMCs, bladder cancer cells and PBMCs from BCG vaccinated individuals 
when challenged with BCG triggered a significant increase in key chemokines and 
chemotactic factors for the recruitment of myeloid cells and lymphocytes to the site. These 
chemokines included MCP-1/CCL2, MIP-1α/CCL3 and IP-10/CXCL3. We observed a 
similar increase in these chemokines quantified at the site of the tumors treated with BCG 
[152]. We found a marked increase in the transcription (Figure 9 and 11) and protein 
production (Figure 12 of CCl2, MIP-1α and IP-10) in different bladder cancer cell types 
when exposed to BCG-disA OE strain compared to controls.  
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Juan Fu et al. measured the efficacy of synthetic CDNs as a STING agonist for their 
efficacy in reactivity against PD-1 resistant tumors in an in vivo and ex vivo mouse for 
colon, tongue, liver and pancreatic carcinomas [36]. They observed a characteristic NF-
κB-dependent TNF, IL-6, and STAT6-dependent MCP-1/CCL2 cytokines in murine 
BMDMs. We found a significant induction of MCP-1/CCL2 in RT4 and NBT-II cells 
(Figures 9 and 11). Further, it was elucidated in cell culture supernatants treated with BCG 
strains, that STING activation in the bladder cancer cells induces MCP-1/CCL2 protein in 
5637 cells (Figure 12). However, RT4 human papilloma cell lines failed to express any 
MCP-1/CCL2 protein in cell culture supernatants collected after 24 hours. Key chemokines 
which have been reportedly associated with increased accumulation of adaptive and 
effector cell types are IP-10/CXCL3 and MIP-1α/CCL3 [152] which was generally 
observed to have increased in the case of BCG treatment in Bladder cancer seemed to also 
be induced higher in the rat bladder carcinoma cell lines (Figure 11). 
Early on in 1996, clinical studies on IP-10/CXCL3 in human non-small cell lung cancer 
had been indicated to be a angiostatic factor which inhibited tumorigenesis and 
spontaneous metastases [155]. Further IP-10/CXCL3 has been shown to be significantly 
increase in the urine of BCG immunotherapeutic received bladder cancer patients. BCG-
disA OE infections caused differential increased in IP-10 in the NBT-II cell lines (Figure 
11) [156]. MIP-1α/CCL3 which is also significantly increased in response to BCG-disA 
OE in the rat bladder carcinoma cell lines, is known to be a prognostic marker for BCG 
immunotherapy in NMIBC (Figure 11). 
Another prominent M1 cytokine which has shown a strong anti-tumor activity in different 
cancers and in vivo and in vitro models is Nitric oxide (NO). In a murine model, it has been 
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shown in pancreatic carcinoma that stromal cells in tumor microenvironment release higher 
NO which is iNOS mediated that is associated with anti-tumor activity. [164] Increased 
relative levels of transcription of the gene encoding iNOS by BCG-disA OE was also seen 
in all the grades and origin bladder cancer cell lines in our study (Figure 9, 10 and 11).  
Previous studies done in the Bivalalqua laboratory, have shown that wild type BCG in their 
MNU induced rat model increased infiltration and expansion of CD4+ T cells [79]. Another 
axis which has shown to increase in bladder cancer cell lines stimulated with BCG-disA 
OE is the inflammasome/IL-1  pathway [157]. Downstream of IL-1  signaling several 
chemokines are induced including CCL2, CCL5 and CXCL12 [158]. Of these CCL2 has 
been extensively shown to be the reason for infiltration and recruitment of myeloid cells to 
the site of inflammation [159]. Further, in a study in an orthoptic model of murine breast 
carcinoma, it has also been shown that IL-1 -induces CCL2 expression in macrophages 
and tumor cells [160]. However, due to the conflicting literature on the role of increased 
IL-1  leading to a more tumorigenic microenvironment, more investigation is required in 
to this axis in the context of bladder cancer [161]. Also, a report by Gaidt et al. posited that 
STING activation can result in targeting a DNA inflammasome as one of the downstream 
targets which can also lead to induction of IL-1  as a co stimulatory effect [162]. We 
observed an increased expression of IL-1  in all the three cell lines stimulated by BCG-
disA OE as compared to the WT strain (Figures 9, 10 and 11.), and there was a 
commensurate increase in IL-1  protein secretion into cell culture supernatants in 5637 
cells (Figure 12). However, like IL-6 and MCP-1/CCL2 responses, differential IL-1  
protein production was not seen in RT4 cells (Figure 12). The increased pro-inflammatory 
microenvironment in cancer cells could potentially contribute to massive recruitment and 
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activation of macrophages and monocytes that can contribute to anti-tumor responses. Our 
results suggest a very similar immune profile as suggested earlier when STING agonists 
are administered at the site of tumor.  
IL-10 gene expression was quantified in the human 5637 (Figure 10) and rat cell line NBT-
II (Figure 11). Notably, IL-10 gene expression was repressed in both cell lines with a lack 
of transcription in the group treated with BCG-disA OE (Figure 11). IL-10 plays an 
antagonistic role  to the IFN  in BCG induced macrophage cytotoxicity to Bladder cancer 
cell lines [163]. 
5.2.2 Therapeutic efficacy of the BCG-disA OE overexpressing c-di-AMP in a MNU 
induced Fischer Rat model of bladder cancer: In the Bivalacqua laboratory, the MNU-
Fischer rat model of bladder cancer was first pioneered and characterized in 2017 [79]. 
They showed that MNU-Fischer rat model of bladder cancer to have a similar pathology 
and immunophenotype to that of human bladder cancer.  
We used a similar intravesical instillation approach for BCG-disA OE strain vs BCG WT 
strain to test the therapeutic efficacy of the recombinant strain (Figure 13). The readout of 
this pilot study was histopathological analysis and scoring of tumor involvement index 
based on the tumor grade and spread in the urothelium. To monitor the effects of the disA 
overexpression immune markers were also measured at the site of tumor induction and 
BCG instillation. At the end of the 16th week after the first instillation, serial ultrasound 
examinations revealed the development of papillary tumors. All specimens (n = 5) at week 
16 had evidence of CIS, papillary Ta, or high- grade T1 urothelial carcinomas (Figure 13c) 
consistent with the 2004 World Health Organization/International Society of Urological 
Pathology classification system. After intravesical instillation of BCG-disA OE, pathologic 
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analysis of the bladder showed a lowered tumor involvement index in the tumors that were 
generated in the BCG-disA OE strain treated animals as compared to the wild type BCG 
Pasteur strain. (P < 0.05) (Figure 14) 
Further characterization of the gene expression profile at week 16 showed a similar 
trend of fold induction in genes encoding IFN , IFN , TNF, MCP-1, MIP-1α, IP-10, iNOS 
and IL-1  compared to controls (Figure 15). While transcription of Il10 was not 
significantly changed, IFN-α and TGF-  were elevated (Figure 15). The role of TGF-  
remains to be explored.  
Thus, the BCG-disA OE treatment group the combination of higher expression of 
gene encoding Type I IFNs along with M1 and Th1 cytokines paired with modest 
expression of genes encoding regulatory cytokines correlates with a potent anti-tumor 
therapeutic effect in this rat model of bladder cancer. However, elucidation of the 








Figure 8. BCG overexpressing disA induces superior Type I IFN responses in all three 
Bca cell lines. Differential expression of interferon- � cytokines in bladder cancer cell lines 
challenged with wild-type and disA overexpression strains of Mycobacterium bovis BCG-
Pasteur. BCa cells were challenged with wild-type and disA OE strains at an MOI of 1:20 
for 5 hours to establish the infection. Uninfected bacteria were washed using ice-cold PBS 
and cells were subsequently incubated for another 3 hours. Expression levels of mRNA 
was measured using a SYBR green-based quantitative real-time PCR. Basal level of 
transcript (mRNA) in untreated macrophages was used for data normalization and hence 
to access relative expression. PPIB was used as an internal control in NBT-II and RNU6A 
was used as an endogenous control for RT4 and 5637 human cell lines. Data analysis was 
performed using 2−∆∆CT method. The graphical points represent mean of three independent 
experiments ± standard error mean (SEM). Student’s t test (*P < 0.05 **P < 0.01, ***P < 





Figure 9. BCG overexpressing disA induces differential immune response in human 
bladder cancer cells (RT4). Differential gene expression in human RT4 bladder cancer 
cells challenged with wild-type, disA overexpression strains of Mycobacterium bovis 
BCG-Pasteur and Mycobacterium bovis BCG-Tice strain. Cells were challenged with wild-
type and disA OE strains at an MOI of 1:20 for 5 hours to establish the infection. Uninfected 
bacteria were washed using ice-cold PBS and cells were subsequently incubated for 
another 6 hours. Expression levels of mRNA was measured using a SYBR green-based 
quantitative real-time PCR. Basal level of transcript (mRNA) in untreated macrophages 
was used for data normalization and hence to access relative expression. RNU6A was used 
as an internal control. Data analysis was performed using 2−∆∆CT method. The graphical 
points represent mean of three independent experiments ± standard error mean (SEM). 





Figure 10. BCG overexpressing disA induces differential immune response in human 
bladder cancer cells (5637). Differential gene expression in human bladder cancer cells 
challenged with wild-type and disA overexpression strains of Mycobacterium bovis BCG-
Pasteur. Cells were challenged with wild-type and disA OE strains at an MOI of 1:20 for 5 
hours to establish the infection. Uninfected bacteria were washed using ice-cold PBS and 
cells were subsequently incubated for another 6 hours. Expression levels of mRNA was 
measured using a SYBR green-based quantitative real-time PCR. Basal level of transcript 
(mRNA) in untreated macrophages was used for data normalization and hence to access 
relative expression. RNU6A was used as an internal control. Data analysis was performed 
using 2−∆∆CT method. The graphical points represent mean of three independent 
experiments ± standard error mean (SEM). Student’s t test (***P < 0.0005, **P<0.001). 





Figure 11 BCG overexpressing disA induces differential immune response in rat 
bladder cancer cells (NBT-II). Differential gene expression in rat bladder cancer cells 
challenged with wild-type and disA overexpression strains of Mycobacterium bovis BCG-
Pasteur. Cells were challenged with wild-type and disA OE strains at an MOI of 1:20 for 5 
hours to establish the infection. Uninfected bacteria were washed using ice-cold PBS and 
cells were subsequently incubated for another 6 hours. Expression levels of mRNA was 
measured using a SYBR green-based quantitative real-time PCR. Basal level of transcript 
(mRNA) in untreated macrophages was used for data normalization and hence to access 
relative expression. Peptidyl-prolyl cis-trans isomerase B (PPIB) was used as an internal 
control. Data analysis was performed using 2−∆∆CT method. The graphical points represent 
mean of three independent experiments ± standard error mean (SEM). Student’s T test 








Figure 12. Increased pro-inflammatory cytokines in response to disA overexpression 
in Bca cell lines (ELISA).  Differential expression of IL-6 (a), MCP-1 (b) and IL-1� (c) 
in two human bladder cancer cell lines (5637, RT4) challenged with wild-type and disA 
overexpression strains of Mycobacterium bovis BCG-Pasteur. Cells were challenged with 
wild-type and disA OE strains at an MOI of 1:20 for 5 hours to establish the infection. 
Uninfected bacteria were washed using ice-cold PBS and cells were subsequently 
incubated for another 24 hours. Culture supernatants were assayed by ELISA for different 
cytokines. The graphical points represent mean of three independent experiments ± 
standard error mean (SEM). Student’s t test (*P < 0.05 **P < 0.01, ***P < 0.001). MOI 






Figure 13. The MNU Model of Bladder Cancer Displays a histopathologic phenotype 
similar to that of human urothelial cancer by Bivalaqua laboratory (A) Fischer rats 
are given 4 biweekly instillations of MNU. For time point analyses, bladders were 
harvested at 8 and 16 weeks.  For treatment studies, animals were given 6 weekly doses of 
BCG and BCG-disA OE from week 8-14.  Bladders were then harvested at week 16 for 
RT-PCR and histology (B) By 16 weeks MNU treated bladders had evidence of increased 
thickening and papillary tumors on ultrasound imaging, and (C) histologic examination 
demonstrated a combination of papillary Ta, CIS, and T1 cancer (arrows point to relevant 





Figure 14. Tumor involvement index of tumor-bearing rats untreated or treated with 
WT BCG or BCG-disA OE. All specimens (n =5) at week 16 had evidence of CIS, 
papillary Ta, or high- grade T1 urothelial carcinoma by analogy with the 2004 World 
Health Organization/International Society of Urological Pathology classification system. 











Figure 15. Immune profiling of MNU-induced Fisher rat urinary bladder tumors in 
response to intravesical therapy using different strains of BCG. Differential gene 
expression in Rat bladder tumor cells after therapy with wild-type and disA overexpression 
strains of Mycobacterium bovis BCG-Pasteur. Expression levels of mRNA was measured 
using a SYBR green-based quantitative real-time PCR. Basal level of transcript (mRNA) 
in untreated macrophages was used for data normalization and hence to access relative 
expression. Peptidyl-prolyl cis-trans isomerase B (PPIB) was used as an internal control. 
The graphical points represent mean of three independent experiments ± standard error 










Future Work  
 
Overall our in vitro and in vivo experiments suggest a favorable immune response 
that characteristically matches with the successful BCG immunotherapy. We used different 
cell types ranging from macrophages (human and mouse), bladder cancer cells (human and 
rat) and a rodent model if bladder cancer to validate our proof of concept that BCG strains 
overexpressing STING agonists can be a better therapeutic option for bladder cancer 
immunotherapy. Key questions that remain to be answered include whether this 
recombinant strain of BCG can induce a long-lasting memory response, the optimal levels 
of c-di-AMP from the recombinant bacteria, whether there are tolerogenic effects and 
whether the recombinant bacterial strains are secreting c-di-AMP inside infected cells 





IFN�: Interferon beta 
IFNα:  Interferon alpha 
Type I IFNs:  Interferon α and Interferon � 
IFNα2b: Interferon alfa 2b 
IFNα2a: Interferon alpha 2a 
IFN : Interferon gamma 
IL-1�: Interleukin 1 beta 
TNF: Tumor necrosis factor alpha 
IL-6: Interleukin 6 
Il-2: Interleukin 2 
IL-12: Interleukin 12 
IL-18: Interleukin 18 
IP-10: Interferon gamma-induced protein 10 
MCP-1: Monocyte chemoattractant protein 1 
IL-10: Interleukin 10 
MIP-1α: Macrophage Inflammatory Protein 1 alpha 
TGF-�: transforming growth factor beta 
Arg-1: Arginase 1 
CCL2: C-C motif chemokine ligand 2 (also MCP-1) 
MDC: Macrophage-derived chemokine 
MIG: Monokine induced by gamma interferon  
STING: Stimulator of interferon genes 
c-di-AMP: Cyclic diadenylate monophosphate 
TBK1: Serine/threonine-protein kinase 
CDN: Cyclic di nucleotides 
NF-κb: Nuclear factor kappa B 
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ISG: interferon-stimulated gene 
PD-1: Programmed cell death protein 1 
CSP: cytosolic surveillance pathway  
c-di-IMP: Cyclic di-inosine monophosphate 
cGAMP: Cyclic guanosine monophosphate–adenosine monophosphate 
cGAS: Cyclic GMP-AMP synthase 
GTP: Guanosine triphosphate 
DAMP: danger-associated molecular patterns 
IRF3: interferon regulatory factor-3 
IRF: Interferon regulatory factor 
iNOS: Inducible nitric oxide synthase 
PAMP: Pathogen-associated molecular pattern 
PRRs: Pattern recognition receptors 
TLR2: Toll-like receptor 2 
TLR9: Toll-like receptor 9 
NOD2: Nucleotide-binding oligomerization domain-containing protein 2 
NLRP3: NACHT, LRR and PYD domains-containing protein 3 
AIM-2: Interferon-inducible protein AIM2, or absent in melanoma 2 
dsRNA: double stranded RNA 
c-AMP: Cyclic adenosine monophosphate 
c-di-GMP: cyclic dimeric guanosine monophosphate 
cGMP-AMP: Cyclic guanosine monophosphate–adenosine monophosphate 
RD-1:  Region of difference 1 gene locus 
STAT6: Signal Transducers and Activators of Transcription 
MyD88: Myeloid differentiation primary response 88 
Sox2: sex determining region Y 
DAI: DNA-dependent activator of interferon-regulatory factors 
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IFI16: interferon-inducible myeloid differentiation transcriptional activator gene 
DDX41: DEAD box helicase 41 
Iκκ: IκB kinase 
ERAdP: endoplasmic reticulum (ER) membrane adaptor 
Ikb: nuclear factor of kappa light polypeptide gene enhancer 
ESAT: early secretory antigen target 
GM-CSF: Granulocyte-macrophage colony-stimulating factor 
NO: nitric oxide  
EGFR: epidermal growth factor receptor 
iNOS: nitric oxide synthase 
DMXAA: 5,6-dimethylxanthenone-4-acetic acid 
mSTING: Mouse Stimulator of interferon genes 
hSTING: human Stimulator of interferon genes 
ADU-S100: Aduro Sting agonist 
MK-1454: Merck’s CDN Sting agonist 
ATP: Adenosine triphosphate 
ADP: adenosine diphosphate 
MAVS: Mitochondrial antiviral-signaling protein 
Poly I:C:  polyinosinic-polycytidylic acid 
disA: DNA integrity scanning protein gene 
PDE: phosphodiesterase  
MUC-1: Mucin 1, cell surface associated 
disA/dacA: DNA integrity scanning protein 
sigH: RNA polymerase sigH factor 
PPIB: Peptidyl-prolyl cis-trans isomerase B 
RNU44: Small Nucleolar RNA 




BCG-disA OE: Recombinant BCG Overexpressing disA gene 
M.tb-CDC 1551: Mycobacterium tuberculosis CDC1551 strain 
M. bovis: Mycobacterium bovis 
BCG-hIL2-MUC1: BCG expressing IL-2 and MUC1 
rBCG: Recombinant BCG 
HIV: Human immunodeficiency virus 
S. aureus: Staphylococcus aureus 
L. monocytogenes: Listeria monocytogenes 
B. subtilis: Bacillus subtilis 
MBT-2: FANFT-induced bladder tumour in C3H/He mouse 
PEC: Bacille Calmette–Guérin (BCG)-induced peritoneal exudate cells of mice 
T24: Human hypodiploidy to hypopentaploidy female epithelial transitional cell 
carcinoma cell line 
J82: human bladder carcinoma cell line 
5637: human bladder polyploidy male cancer urinary bladder grade II carcinoma cell  
UMUC-3: Human hypertriploid male epithelial transitional cell carcinoma cell line 
TCCSUP: Human hypotetraploid female grade IV transitional cell carcinoma cell line 
PBMC: peripheral blood mononuclear cell 
MB49: Cells from C57BL mouse bladder epithelial cells transformed with chemical 
carcinogen 7, 12-dimethylbenz[a]anthracene (DMBA) 
J774A.1: Mus musculus BALB/cN derived macrophage cell line 
THP-1: monocyte lineage cell line from Human acute monocytic leukemia 
RT4: Human tetraploid male derived transitional cell papilloma cell line  
NBT-II: Nara Bladder Tumor No. 2 cell line induced by N-butyl-N-(4-hydroxybutyl) 
nitrosamine in rat cells  
RAW 264.7: Mus musculus derived Macrophage/ monocytic cell line derived from 
Abelson murine leukemia virus-induced tumor 
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CT26: N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon 
carcinoma cell line 
DCs: Dendritic cells 
NK cells: Natural killer cells 
CD4: Cluster of differentiation 4 
CD8: Cluster of differentiation 8 
BMDM: Bone-marrow-derived macrophage 
Th1: Type 1 T helper 
Th2: T helper 2 cells. 
Th17: T helper 17 cell 
Tregs: Regulatory T cell 
CD: Cluster of differentiation 
M1: Classically activated macrophages 
M2: Alternatively, activated macrophages 
NMIBC: Non-muscle-invasive bladder cancer 
MNU: N-Nitroso-N-methylurea 
CIS: Carcinoma in situ 
TUR: Transurethral resection 
PEGylated: Amalgamation of polyethylene glycol 
C22b2b: Immunocytokine comprising tetrameric. IFNαβb coupled to hLβ4γ 
hL243: humanized monoclonal antibody that is specific for HLA-DR 
FANFT:  N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide 
BBN: N-butyl-N-(4-hydroxybutyl)-nitrosamine 
TME: Tumor microenvironment 
Ta: non-invasive papillary carcinoma, which is grown toward the center of the 
bladder and has not spread to distant sites nor lymph nodes 
T1: The tumor has spread to the lamina propria) but not bladder wall muscle 




SCID: Severe combined immunodeficiency 
PCR: Polymerase chain reaction  
ELISA: Enzyme-linked immunosorbent assay 
OADC: Oleic Albumin Dextrose Catalase 
CTAB: Cetyl trimethylammonium bromide 
qPCR:  real-time polymerase chain reaction 
SYBR: SYBR Green I  
RPMI:  Roswell Park Memorial Institute media  
DMSO: Dimethyl sulfoxide 
FBS: Fetal Bovine Serum L929- Mus musculus L cell, L-929, derivative of Strain L 
PBS: Phosphate-buffered saline 
SEAP: Secreted alkaline phosphatase 
MOI: Multiplicity of infection 
DMEM: Dulbecco's Modified Eagle Medium 
7H9: Middlebrook 7H9 broth 
7H11: Middlebrook 7H11 agar  
SEM: Standard error of the mean 
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